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ABST RACT
Henry and Ierne (I9{>8)described an interesting phenomenon . when SRIK" s werc
used as antigen, the presence of IgG antibody prier to injcction of antigen led to a
suppressed respo nse. In contrast. pre-existing IgM resuhrd in an increase of the primnry
immu ne response. The aims of this project were twofold. to determine if the same
phenom enon is observed when using either human B cells or mouse trnnsfl'Clctl
fibroblasts, HS antigens; to study the feasibility of using IgM enhancement to im prove Ihc
yield of antigen-specific hybridoma s from mice against HLA·D r and DR.
Studies were conduc ted using mice immunised either with a mo use transfec tantce ll
line e xpressing HLA-DP (l2S. 4) or a human 8 cell line (RAJ!). Preliminary expe riments
uncovered an unexpec ted reverse dose response ~ hen U."iA ce lls were used as
immu nogen. Pre-trea tment o f mice with antibodies to monomorphic IlLA-I>I>
determ inants inc reased and suppressed the responses as predicted; were stati!ll:ically
significant with both Raji and L25A . In a second expe riment, doubting of the IgM dose
led to an unexpected diminution of the primary response againM 1..25 .4 and revealed that
the half life of the administered IgM antibody appeared to be lengthe ned.
Experiment!> were then co nducted to determin e the value of lg M pretreat ment in
the creat ion of hybridoma s specific lor HLA·DP and HLA-DR epitope s. Mice were
pretrea ted with varying amounts of IgM antibody and then immunized . Three days later
their spleens were removed, cells counted and fusions performed. Spleen size was found
to be increased in a stepwise fashion with increasing doses of ISM past a previously
described antigen induced plateau . The low dose of 19M produced spleens predominately
composed o f B cells, increasing the IgM dose decreased the 8 cells but increa sed the T
cells. The IgM pretreated animals gave a 22.8% yield of specific hybridomas whereas
the co ntrol group produced an 8%yield of specific hybridomas. Within the 19M
pretreatment group, 96%of the selected hybrids originated from the low dosage group.
indicating that there may exist an optimum pretreatment dose for IgM. These preliminary
experiments support thc potential of specific antibody pretreatment in the modulation of
the primary response and the development of antigen-specific hybridcmas.
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CHAPTER I
INTROD UCTION
1. [ Human Leukocyte Antigen - DP Project
One of the requirements for successful transplantation is to ensure proper matching
of the recipient and donor atthe Major HistocompatibilityComplex (M HC) level. The
human MHCcontains a group of hig hly poly morphic genes, products of which are called
human le ukocyte antigens (HLA) molecules and whic h are expressed on a variety otceu
surfaces. There a rc two classes of MHC molecules. Class I and II. The Class II genes
consist of DR, DQ and DP loci. DP is a fully functio ning MHC molec u le, presenting to
T cells a nd showing MHC restriction . Until now the emphasis for tissue matc h ing has
been on the DR and DQ loci.
In a collaborative p roject tha t is presentl y unde rway, the aim has been to produce
monoclonal antibod ies that react with polymorphic determinants on HLA·DP molecules
for usc in tissue matching. The produc tion of antibodies to the diffe ri ng epitope s has
proven to be a difficult undertaking , and it was suggested thai it might be possible to
make use of the manipulation of preexisting an tibody levels to improve the immunisation
schedules and co nsequently to increase the y ield of h ybridom as specific forepttopes of
the DP molecules .
1.2 Basic Phenomenon Shown with Red Cells a s Antigen
An inte resting oc currence has been documented in the literature: whcn sheep red
blood cells (S R BC)are used as an antigen , the pre sence o f specific IgG antibody in the
blood at the time of inject ion of antigen can cause the animal' s response to be suppressed
(Heyman,I990 ; Heyman,1988: Heyman eral. 1988 : Quintana ct el, 1987). Por cmmplc
one study reported more than 99 % of the immune response was suppressed in such a
manner (Sincla ir,1978). On the other hand, pre-existing specific IgM (macroglobulin) <It
the time of ant igen injection result s in an increase in the primary immune response (Coulic
and S nick,1985 ; Dennert,1971; Henry and Jeme. 19 68; Heyman etet. 1982; Heyman and
Wigzell,1985; Heyman et al. 1988; Powcll eta!. 1982; Reiter aet. 1986). A practical
example of the regulating capacity of pre-existing antibodie s exists in humans as shown
by the injection of IgG anti-rhesus D anti bodies in to Rh negative mothers at the time of
delivery of their Rh+ ba bies. Th is treatment has significa ntly reduced the frequency o f
iso-im munisation agains t the Rhesus D antigen and hence has dec reased haemoly tic
disea se of the newborn (Clarke etal . 1963). It wa s later shown by Pollack that antibody -
media ted imm une suppre ssion mechanisms were res ponsible for this effect as opposed to
simple clearance of the antigen antibody (Pollack et ei. 1971).
1.3 Review of Lit erature Relating to Primary Immune Response Modula tion
1.3. 1 Earl y History
To understa nd how this line of investi gation first started one can go back to the
ear ly 1900' s, In 1909, Theobald Smith demons trated that injection of part ially neutralized
diphtheri a toxin-a nt itoxin mixtures induced a n titoxin fo rmation in experimental an imals
bu t that immuni ty d id not re sult from mixture s containi ng a sufficient excess of a ntitoxin
(S mith, 1909) . The results of these experiments were e x tended to the study of add itional
antigens such as tetanus to xoid (IT), sheep red blood cells and bacteriop hages (U h r and
Baumann . 1960). On e of the many que stions later raised from Smith's experime nt was :
Do prc-exis ting antibody levels have any effec t on the result o f immunisation?
It was not until the 1960's that significa nt work and results started to appea r in Ihe
lite rature conce rning this questio n. Investigators began 10theorize and prove tha t pre-
ex isting antibodies could regulate the primary immune response in both enhanc ing and
suppressive ways.
1.3 .2 Land mark Study by Claudia Henry & N iels Iern e
C la udia Henry and Niels Jem e, in 1968, inv estigated the idea of pa ssi vely
administere d antibod y having an effect on the p rimary immu ne response. The study used
in excess of 1000 animals . purified antibodies from a varie ty of methods, a varietyo f
antigenand antibody doses anda varietyof immuniza tiontime schedules. The focusof
theexperiments Wa5 10determine the effect ofprc< ltisring75 and 195 antibodies on the
result of immunizationof micewith 5RBC on theprimary immuneresponseas measured
by plaque assays. The results clearly showed that all 7S preparations suppressed the
response while all 195 preparations enhanced the response. 'tbe IgM mediated increase
wasa fifteen fold enhance mentin the number ofplaq ue formingcells (Henry and Jemc .
1968). However , in earlier studics (Moller and Wigzell, 1965; Pearlman,1967), it was
shown thatl gM givenat highdoses (comparable to the high dosesof the Henry and Ierne
experiment) could besuppressive. The Hen ry and Jeme expe riment (Figure I ) includ ed
a broad spectrum of doses of IgM antibody andall levels of dosage were successful in
providing an enhancing effect. Thc Henry and Jeme studyclearly de monstrated forthe
firsttime. theenhancingeffectof pre-existing IgM an tibody and the suppressive effecto f
IgG antibody.
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MOLAR CONCENTRATION OF ANTIBODY
rieur.: 1 : Ekvat ion hy speelflc19 5 3ll1ibllrJy. anddep ression by specific 75 antibo dy of the
primary immune response n t'miceto a single lntr aveeous injection of4 X lOSSRBC as measured
by count ingthe tota l number ofplaque forming cellspe r spleen. Theopen symbols (including
11k! triangles) represent the average responses of groups o f mice th at received 195 anti body, the
Slliid ct rcks represent the average responsesof groupsth at received 75antibody. Eac h pointis
Ilk!mean number o f plaque formingcellsper sp leenof 20-50 mice afterdeductingthe number of
had gro undplaque forming censshown(Henry andJern e.I 968).
1.3.3 IBM Mediated Enhancement
Curren t knowledge on the effect of pre-existing IgG and IgM ant ibody is q uite
detailed but un fortuna tely not co mplete . The exact mechan ism andl or mechanisms ofthc)C
an tibodies is still unkn own. There is. however . a conse nsus in lhe literature that IgM
an tibody has an enha ncing e ffect on the primary response . In the case of the IgG
ant ibody the re is a paradoxical effect; in some incidences the immune response has been
shown 10 be enhanced while in others it has been suppre ssed.
1.3.3 .1 Speci ficity Characteristics
From the He nry and Jemc (1968) study it was sho wn tha t antibod ies of the IgM
class can ha ve an enh ancing e ffect on the prima ry immune response. It is now known
that whether particula te (Wason .I973) or soluble (Enriq ues and Klaus.1984) antigen.. are
used , theenha ncement by IgM is still observab le.
ColJisson et s t. (1983) further investigated the speci ficity ofl gM enhancement by
simul:.aneously injec ti ng two an tigens together with the IgM antibody directedonly against
one of them. Only the respo nse 10 the antigen against w hich the IgM was directed wa~
enh anced. Th is was shown bot h inan erythrocy te system with ox and human erythrocytes
and in a pro tein system with ova albumin (OA) and 2,4-d initrophenyl - bovine serum
albumin (DNP -BSA). This specificity has been furthe r character ized as being
antigen/panicle specific but not epitope specific. Heyman et s l. (1982) used the fact that
SRIJC and goal red blood cells (GRBC) cross-react at both the T and B cell levels. After
IgM-anti-SRnC monoclonal antibody administration, GRBC or SRBC were used as the
immunogen. They then assayed for plaque forming cells against GRBC and SRBC. It '
was found that the monoclonal antibodies that cross-reacted with GRBe enhanced both
the anti-GRBC and the anti-SRBC response. However, monoclona l antibodies used that
did not cross-react with GRBC did not give any enhancement when GRBe was the
immunogen. These results suggest that the 'lgM antibodies enhance via binding to the
erythrocytes, thereby allowing other epitopes on the same erythrocyte to display enhanced
immunogenic properties' (Heyman et st. 1982). Since these experi ments. the effects has
been clearly characterized as being antigen/particle specific but not epltope specific.
Using a malaria vaccine. Harte and his group investigated whether specific
monoclonal IgM antibodies could be used to enhance the response to a blood-stage murine
malaria vaccine, The group found that small amounts of a monoclonal anti-parasite IgM
could spectflcilt y enhance both primary response and memory cells in response to
vaccination. These results were supported by survival after infection, In offspring of the
murine mother, where vaccination was ineffective for up to eight weeks due to the
presence of maternal IgG. it was possible to overcome the inhibition of the maternal
antibodies when the IgM monoclonal was administered before the vaccine, This was
described as being made possible by the increased concentrat ion o f antigen in the spleen
as measured by the injection of radiolabellcd vaccine measured 24 hours a fter injection
in contro l mice [Harte et al. 1983).
1.3.3.2 Basic Criteria
It was Dennen (1971) that first described the localiZ<1tion of the antigen hcin~
enhanced in the spleen by pretreatment with specific IgM antibody. Dcnncrt IabeI1c:d
antigen with ' ICr and injected it afte r IgM antibody administration. After ten minutes the
animals were sacri ficed and the rad ioactivity o f the spleens assayed, Compared to contro l
animals which received no IgM antibody, there was a len to twenty fold increase in
antigen uptake when animals were treated with the specific IgM antibody. If IgM works
by trapping the antigen - antibody complexes then there should also be localiza tion found
in other organs, such as the liver. However, the concentrations of antigen in the liver was
not enhanced by the pretrea tment o f IgM antibody (Dennert. 1971) This findiJig may be
exptalred by the fact that the blood content and, thus, the background of antigen in the
liver is too high to see further IgM induced concentration of antigen. Dennen tcMOO a
variety of rime intervals between IgM and antigen administration todcterminea n optim um
schedule . It was seen that administration of antibody one to two hours before antigen
injection would result in sufficient enhancement (Dennert,J97 1). From Henry and Jerne
(1968) it was established that stimulator activity of IgM depends on the amount of
administered IgM antibody as well as the antigen dose. However, in Dennen's
experiment. augmentation by IgM could only be observed when antigen doses were at
suboptimal levels (Oennert, 1973). This is in contrast to Henry and Ierne's experiment
in which they demonstrated a linear relationship with no evidence for a plateau or
levelling off. Thus, from these experiment s it was established that certain criteria must
beoptimized for the enhancement 10 be observed; specifically, the dose of antibody, and
an optimum time frame of antibody administration. Dennert also provided a clue as to
the mechanism involved, showing that the antigen localization in the spleen was increased
by the enhancing IgM antibody .
1.3.3.3 In Vivoversus In l1tro Experiments
The in wvo investigation of the response to heterologous erythrocytes in the mouse
by Hcnry and Jeme ( i968) was also followed up by John Schrader in a series of
experiments jhar examined the effect of specific IgM antibodies on the in vitro primary
response to sheep erythrocytes by mouse spleen cells. Schrader's clai m was thai in such
a system the amount of antigen and antibody to which a given population of
immunocompetent cells is exposed may be controlled with much greater precision than
in thc in WKI situations, where compartm entalization of both antigen and antibody may
complicatc interpre tations at many levels (Schrader, 1973). Schrader (1973) in replicating
Henry' s and Ierne's 1968 cxperi ment, used antibody preparations of lgM shown by Henry
and Jemc (1968)10 beenhancing; these had marked suppressive propert ies in vitro, while
the in wvo experiments performed with the same antibody replicated Henry and Jerne's
(1968) results. The antibody was prepared exactly as stated in the original experimen t.
The results demonstra ted a paradox ical effect of the in vim and in vitro ac tivities of
passively administered IgM.
In 1973 William Wason also investigated the effects of pre-existing antibody in in
vitro and in vi100 experimental designs. His experiment compared the effect of antibody
given before and after antigen both in viwand in vitro. The in lit ro experiments allowed
for "control" over variables such as an accurate quantification of the antibody half life.
and elimination of the possibility of the IgMaltering antigen distribution at the tissue level
or affecting the selection of ci rculating cells into the spleen. The half life of IgM
antibody in the mouse circulation has been reported as one day (Britton ct .11. 19(8 )
whereas the half life in vitro was found to be greater than six days (Wason,1973). His
design allowed him to test the hypothesis that the IgM antibody caused augmentation of
the immune response in vivo. by altering antigen distribution and thus increasing the
amount of effective immunogen in the spleen. Injected IgM anti-SRBC antibody was
found to have a dual effect on the primary immune response in mice. The response 10
SRBC was either augmented or suppressed depending on whether the IgM antibody was
given before or after the immunizing dose of SRBC. In the in vitro experiments, IgM
anti-SRBC antibody suppressed the response of cultured mouse spleen cells 10 SRBC
under all the conditions that were tried. Therefore, the findings were consistent with the
hypothesis that IgM antibody increases the response in vilV by altering antigen
distribution, a conclusion which had been suggested by Dennen's work (Dennett, 1973).
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1.3.3.4 T Cell Component
Another characteristic of IgM mediated enhancement is its dependenc y on T-cells.
Dennert, in testing to see if anti·SRBC IgM co uld substitute for the helper function of T
cells, opted to test its action in thymectomized mice. These mice were thymecto mized
at the age of 3-4 weeks. irradiated and protected with synge neic fetal liver cells.
Experiments were conducted. as before , with SRBC as the antigen. When low or high
doses of antigen were administered and the plaque assays performed , there was no
detectable stimulation by IgM. Dennen also conducted in vitroexpe riments. When T cell
deficient spleen cells were used, and low doses of IgM were given , there was a small (but
not significant) improvement o f the SRBC response. Th is IgM enhancement was lower
than that found in experiments in which 8 cells were mixed with sensitized T cells
(Dennen, 1973). Collisson et st. in 1983 were also interested in the T cell component.
In experime nts conducted with nude mice which lack functionally active mature T cells,
there was no potentiation of the primary response (Collisson et al . 1983), confirming the
results described earlier by Dennett .
As previously mentioned, non-speci fic IgM administered prior to the antigen docs
not produce any enhancement. However, there is one study that showed enhancement of
anti-horse red blood cell response by monoclonal anti·SRBC IgM antibody which fails to
bind to the horse red blood cells (Heyman et st . 1982). It was the belief of Collisson et
.11. that there may exist a cro ss-reactivity at the T cell level, to exp lain this type of result.
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They chose two proteins that do not cross-react at the T · helper cell level. bovine serum
albumin (BSA) and ova albumin (OA), for further experiments. In adopt ive transfers of
spleen cells fro m mice injected with 2,4-di n itropheny1 (DNP)-OA alone, BSA a lone or 11
mixture of the two, into sublethally irradiated mice, the effect of treatment with IgM anti-
2.4,6-trinitrophen}'J (TNP) was studied. Since TN P and DNP cross-reac t. IgM with TNI'
specificity was used to modify responses against DNr coupled molecules. A distinc t
specificity wasobserved . Only in the case when anti-FNp IgM antibody and DNI' -USA
(antigen) were given did the naive mice. wh ich received T cells specific \0 nSA , show
an observ able increase in the antibody response to BSA and DNP (remarkably .1fourfold
enhancement). This experiment also included gro ups where the effect of anti-hapten
antibody on the pure anti-protein response against nenccnjugated USA or OA was studied.
No effect was observed in either of thesc ca ses (Cotllsson ct ,11.1983). Based on previous
work by this gro up the authors were able to show thc existence of IgM Fc receptors on
murine T cells (Lamo n er 31. 1976). Fun hermore. removal of this distinct T cell
population (lgM-Fe-recep tor positive T cells) from a primed T-cell population reduced the
helper T cell activity in a passive transfer system (Anderson ct et. 1979), Janeway cf III.
(1971) have shown that one subpopulation ofT helper cells requires the presence of U
cells 10 function. It is possible that such antibody dependent T helper cells (unciion by
binding IgM complexes via IgM Fe receptor s. These findings support the claim that IgM
Fc receptors on helper T cells play a functio nal role in regula tion of antibody responses
in WKJ(Collisson et al. 1983).
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1.3.3.S Role of Complement
In 1988 Heyman and colleagues conducted experiments to study the importance
of complement facton on the ability of lgM to induce enhancement. In these studies three
different approaches were used. In the first, a mutant IgM antibody unable to activate
complement was used. In the second, mice genetically deficient in complement were
utilized. Finally , mice depleted of complement by treatment with cob ra venom factor
were produced. In the first approac h, two monoclonal IgM-anti-TN P antibod ies were
used. One of the antibodies contained a point mutation in the Il chain constant region,
therefo re, could not activate co mplement. The nor mal IgM antibody enhanced the
response in a dose-dependent fashion, whereas, the mutant IgM antibody did not produce
any sig nificant enhancement (Heyman ct al. 1988). When complement deficient mice
were used. it was shown that IgM can produce an enhanced response in CS-deficient AKR
mice, thus. demonstrating lhat at least the late acting complement compone nts, CS-C9,
are not critical (Heyman et Ill. 1988). In the third case, mice were treated whh cobra
venom factor and then injected with poIyclonallgM·anti-5 RBC. II was previously shown
that in ";10 doses of cobra venom factor causes transient depletion of plasma C3 to leu
than SlJL of normal levels (Pepys, 1975). After a period of time the mice were then
injected with the antigen, SRBC. Th is treatment abolished the six-fold enhancing effect
on the di rect plaque forming cell response of ISM seen in control mice immunized the
same way. These studies clearly indicate that the enhancing effect of the IgM antibody
is dependent upon complement factors, prob,'lbly those acting before C5 .
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1.3.3.6 Postulated Mechanisms
Of the postulated mechanisms of IgM enhancement, one hypothesis suggests !lul
antigen-antibody-C3b complexes are trapped ill the spleen. possibly on the follicular
dendritic cells. which carry complement receptors (Dennert. 1971.197J: Heinen c.'f.. I.
1985). Supporting evidence comes from studies showing failure of IgM pctenuarion when
IgM is injected after the antigen indicating Ihat the immune complexes are in some way
responsible for the enhancement. in addit ion 10 evidence provided by the in 111m
experiments (Schrader, l973). The trapped immune complexes then can capture n cells
carryi ng antigen-specific receptors and C3b receptors (sec Figure 2, page 15).
Crosslinked C3b is known to stimulate activated B cells to proliferate and secrete
immunoglobulin (Erdei et a/. 1985). Additional help may be provided by antigen-specific
T helper cells that are activated more efficiently due to increased ccnce nuutions of antigen
ana, possib ly, by IL·I secretion by the follicular dendritic cells (Heyman et 11/. 198M;
Heyman,I990b).
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Figure 2 : Theoretical explanation of IgM-mediated enhancement. Hypothesis: IgM • antigen
complexes activate complement andstimulate B cells via crosslinklngof complement and antigen
receptors. In addition, increased antigen localization (via complement receptors) on follicular
dendrith: cells in germinalcentres may play an important role [Heyman, 1990b).
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1.3.4 (gO Mediated Suppression
Heyman and Wigzell with the aid of a simple enzyme-linked immunosorbent ass..'\Y
(ELISA), were able to show that mice pre-treated with IgO antibody and then
administered antigen showed suppressed levels of both IgOand IgM antibody levels in the
primary response (Heyman and Wigzell.1985).
1.3.4. 1 Specificity Characteristics
IgO antibodies can specifically suppress the humoral immune response against
particulate as well as soluble antigens (Henry and Jerne,1968; Bruggemann and
Rajewsky, 1982; Heyman and Wigzell, 1984). Studies have shown that the IgG
suppression is non-cpitope specific but is antigen/particle specific (Bruggemann and
Rajewsky, 1982). IgO antibodies binding to one epitope suppress the antibody response
to all epitopes of the particular antigen used (Heyman, 1990b).
Wiersma etst. (1989) studied the ability o f IgO 10 modulate the immune response
against TNP-SRDC and a control antigen , horse red blood cells (HRBC) with the use o f
a polyc1onal antibody and panel of nine IgO TNP·specific monoclonal antibodies. Roth
antigens (TNP-SRBC and HRBC together) were injected into mice one to two hours after
administration of the antibody. T he plaque forming cell responses against SRBC and
HRBC were then determined . Five of tbe nine IgO TNP specific monoclonals and the
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IgG anti·TNP specific polyc1onal antibody were able to suppress the response to SRBC
whereas there was no significant suppression observed on theHRBC response (Wiersma
n sl : 1989). Wiersma's group also examined the antigen binding properties of the
various antibodies used. The antigen binding capacity was tested in three different assays
: binding to SRBC<oupled TN P in an ELISA; ammonium sulphate precipitation by the
Farr technique; hemagglutination. II was found that the antibodies that were unable to
suppress the response in "100gave significantly weaker binding results with SRBC as
compared to the antibodies that were suppressive (Wiersma cl al. 1989). Thus,
suppression is antigen specific, ron-epitope specific, and the antigen binding ability
(affinity) of the IgG antibody appears to be of importance.
1.3.4.2 Ability of Various Subclasses to Suppress
It has been shown by a number of investigaton that all subclasses of IgO can be
suppressive (Bruggemann and Rajewsky,I982; Heyman and w lgzell, 1984).
Bruggemann's and Rajewsky' s main aim wps to study the role of antibody class in
feedback inhibitton. Feedback inhibition has been one of the proposed mechanism of IgG
suppression and it implies that the IgO antibody is able to direct a negative signal or able
to block the productive phase of the primary response. Binding of antigen-antibody
complexes to Fc receptors may playa crucial role since Fe receptors of various isotype
specificities have been found on T and B lymphocytes and on maerophages (UnkeJess et
al. 198 1). It was Bruggemann's and Rajews ky 's belief that these receptors could well
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confer isotype specificity to feedback inhibition. They found that suppression wasequally
achieved with IgGu IgG1. , IgG) and IgGl~' Thus, they concluded that antibody feedback
inhibition is not a function of a particular IgG subclass. and that the antibody needs no
property other than its affinity to the antigen (Bruggemann and Rajewsky, 1982).
1.3.4.3 Experiments involving F(ab') l Fragments and the Fc Receptor
As ear ly as (969, investigators had been curious as to the role of the Fe fragment
of antibody in the signalling process of an antibody response. Sinclair was specifically
interested in ascertaining whether binding of antibody to antigen. and the masking or
antigenic determinants . are sufficient to induce the suppression of the immune response.
In Sinclair' s experiment he was able to remove the Fe portion of the IgG antibody. In
this way the binding of the antibody to antigen was not altered. The resulting P(ab') 1
portion was tested for its ability to inhibit the primary immune response. He found that
the F(ab'h portions were 100 to 1000 times less suppressive than complete antibody
(Sinelair, 1969). These results were later confirmed by others , Heyman (1990) and
Gordon and Murgita (1975). Heyman (1989) again investigated the role of the Fe regions
of IgG antibodies in IgG mediated suppression using antibodies blocking cellular Fe
receptors. Heyman found that when she used these antibodies it reversed the ability of
the IgG antibodies to induce suppression (Heyman,1989). From these experiments it may
be concluded that interactions between Fe regions and membrane bound, or possibly
secreted Fe receptors, are crucial events in IgO mediated suppression.
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1.3.4 .4 Density Factor
It has been found that thehigher the density of lgG antibodies bound to thespecific:
antigen, the more efficient the suppression of the response by the particular 180 antibody
(Quintana et af. 1987). Two factors involved in the suppression. therefore, are affinity
and the number of epitopes recognized by an adm inistered IgO preparation. This may
explain why some researchers have found that polyclonal IgG is usually more suppressive
than monoclonal lgG (Bruggemann and Rajewsky, 1982; Wiersma etaf . 1989). Some
researchers have commented on this. suggesting that there may be a threshold de nsity
divid ing monoclonal IgG antibodies into those that can suppress and those that do not
suppress (Wiersma et al. 1989). When mixtures of different monoclonal IgG antibod ies
are used the suppressive effect of the individual monoclonals is additive (Heyman and
Wigzell. 1984). It has been suggested that the link between the suppressive effect and
density of IgG on the antigens can beexplained by increased binding to Fe receptors by
the high-density comp lexes (Heyman.1990). An interesting experiment to test this would
be to see if a divalent antibody (one with two specificities) would give more 5Uppression
as compared to a monoclonal antibody.
1.3.4.5 In Utro Experiments
A number of researchers have confirmed that IgG induced suppression is
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observa ble in vitro. (Abrahams et s l. 1973: Kappler et e t. 1973; Ho ffmann et Ill. 1974).
In one such expe riment spleen cells were cultured with SRBC alone or with SRBC and
anti-5RBC IgG antibody ; a number of different ratios o f antigen to ant ibody were used.
The plaque fonnin g cell kinetic s were measured over a number of days. The result s
clearly showed that cultures containing antigen-an tibody complexe s given at the beginning
of the culture suppressed the appe arance of plaque forming celt s at all subsequent days
of cell culturing (Oberbam scheid t and xolsch. I978). The degree of suppression depended
directly upon the concentration of antibodies in the co mplex. These experiments indicate
that antibody - antigen comp lexes in vitro can efficientl y inhibit the induction of antibody
formation .
1.3 .4 .6 Role of T Cells
Oberbamscheidt and Kelsc h (1978) also examined the role of T cells in IgG
mediated suppression with the aid of nude mouse (nu /nu Balb/c ) spleen cells in an in vitro
set of experiments. It was first establi shed that spleen cells froM nu/n u Raible mice could
respond (produce antibodies) to sheep red blood cell s or to TN P-SRBC in the presence
of supernatant co ntaining thymu s-replacing factor ob tained from concanavalin A activated
normal spleen cell s. It was found that this response cou ld be blocked if anti-SRBC IgG
antibody was added to the mouse spleen ce ll culture. The degree of suppression was
. similar to that found when nonnal spleen cells were used. With this particular design the
researchers were confident that the T cells were not directl y involved in suppres sion. but
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the possible effect of a suppressive T cell factor in the supernatant of the concanavalin A
acti vated spleen cells was not included. At this time, concanavalin A activated T cells
we re considered to be suppressive. To test this further, the effect of antigen-antibody
co mplexes on nu/nu Raible spleen cells in the presence of antigen and lipopolysaccharide
(I. PS). a non-T cell stimulator, was studied. Again it was shown that the cultures
co ntaining the antigen-antibody complexes hada significantly suppressed response. The
researchers were then concerned with the possibility that anti-Thy-1.2 sensitive immature
T cells might mediate antigen-antibody induced suppression. The suppression of the anti-
SRBC response in c ultures of anti-Thy-1.2 treated normal or nu/nu Balb/c spleen cells
supplemented with thymus replacing factor or LPS was then examined. Once again,
immune complexes suppressed the immune response showing clearly that the suppression
of IgG antibody is not dependent upon the presence of T cells, (Oberbamscheidt and
Ko lsch,1978). 1be data suggests that antibody - antigen complexes directly block B cells
(or their access to antigen) in such a manner that they cannot be affected by maturation
signals, such as LPS or thymus-replacing factor.
Theaim of Hoffman and Kappler (1978) was 10 investigate the inhibitory action
of tgG antibody in relation to the Fe receptor. They found that inhibitory antigen .
antibody complexes did not effect fhe acti vityofT helper cells or antigen reactive B cells.
The y took advantage of fact that SRBC and burro red blood cells (BRBC) cross-react at
the T-cell level, but, not at the B cell level. SRBC primed helper T cells stimulated
fo rmation of antibody \0 both SRBC and BRBe . They were able to shew that non-cross
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react ing antibody against SRBC inhibited the production of antibody to SRBC but did nOI
diminish the helper effect of SRBC pri med T cells on BRBe reactive I: cells.
Conversely, TNP-reac\ive B cells (responding to TNP coupled SRBC and BRBC) failed
to produce antibody to T NP-SRBC in the presence of antibody to SRBC, but, remain
responsive to TN P-BRBC in such conditions, The results indicate that neither T cells nor
B cells were immediate targets of the suppressive antibody, Hoffman and Kappler Were
then curious to see if the process of cooperation between T and B cells was altered. TIley
tested three types of antibodies to SRBC in experiments investigating the inhibition of a
anti-SRBC response in spleen cell cultures : IgG rabbit anti-SRBC, IgG rabbit SRne-
F(abh and chicken anti-SRBC (Fe portion unable to recognize mammalian cells). All
three inhibited the produc tion of an anti·SRBC plaque forming cell response at high
concentrations. However , only intact rabbit antibody was inhibitory also at a low
concentra tion. The addition of serum containing tumour necrosis factor (p reviously shown
to replace the helper signal and support the production of antibody in identical spleen
culture cells depleted of T cells) reversed the suppressive effcet at low co ncentrations hut
not at high concentrations of rabbit ami-SRBC antibody. The inh ibitory effect of
increased concentrations of rabbit anti-SRBC-F(abh antibody or of chicken anti-SRBC was
not reversed by the "tumour necros is serum" . Thus, these results support the belief that
antibody can inhibit the cooperation o fT and B cells. This inhibitory ef fect was described
as being "reversible by replacing the signal which results from that cooperatio n". Th us,
the ideas that T helper cell activ ity is unaffected and that T - B cell cooperarlon was
disturbed by the inhibitory antibody were supported (Hoffman and Kap plcr, 1978).
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1.3.4.7 Role ofCompJement
Heyman c/ al. (l 988b) investigated the role of complement in IgG mediated
suppression. In one experiment they chose two different IgO anti-TNP antibodies. one
that could activate and one that was unable to activate complement. Both antibodies
bound equally well to the antigen, sheep red blood cells coupled with TNP. To avoid
detecting suppression caused by the blocking of antigenic determinants by
immunoglobulins, the researchers chose to measure the anti·SRBC response as opposed
to the anti-TNP response. Mice were given the antibody preparation one , two hours
prior to administration of antigen and plaque assays were performed on day five. The
non-complement activating antibody suppressed up to 94% of the SRBC antibody
response. However. this degree of suppression was in the same range as that of the
complement activating antibody. These researchers also presented data showing that
polyclonal IgO anti-SRBC antibodies were as efficient as suppressors in mice depleted of
more than 90% of their serum C3 by treatment with cobra venom factor, as they were in
normal mice. The response to sheep red blood cells in AKR mice. genetically CS
deficient. was also efficiently suppressed by IgO antibodies. These data clearly support
the belief thai complement factors are nor involved in IgG mediated suppression of the
primary immune response (Heyman a aJ. 1988b).
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1.3.4.8 Memory
Heyman and Wigzell (1985) conducted experiments to determ ine if IgG mediated
suppression of the primary response also affected the secondary response, i.c . suppressed
the production of memory. Mice were either primed with SRBC alone or with polyclonat
IgG anti~S RBC antibodies followed by SRBC. at a dose known to give optimal
suppression. This suppression was confirmed one week later by a direct plaque assay
using a sample of the animals. After 24-90 days. spleen eells from other primed an imals
were transferred to irradiated synge neic hosts together with antigen. T he seco ndary
response was measured by d irect and indirect plaque assays. Both IgG-SRBC and SRBC
primed cells gave a higher response than did unprimcd cells. However, compared with
groups primed with SRBC alone, the response was grea tly suppressed in the IgO treated
grou ps. This experiment led the invest igators to conclude that the suppression of the
prim ary antibody response, caused by passively administered IgG. is also extended to the
secondary response which showed inhibited induction of memory (Heyman and wigz cll ,
1985).
1.3.4.9 Aeccssory Cell Involvement
B cell involvement has also been repo rted in the literature. It has long been
recogn ized that derivatives of C3 playa vital role in phagocytosis (Ehlenbergcr and
Nussenzwe ig, 1977) As mentioned before, no decrease in suppression was obscrved in
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animals depleted of complement. Kolsch ' s group conducted in vilTOekperiments in which
macrop hages were depleted from the c ultures. These macrophage depleted cultures
shewed the same degree of suppression as non-depleted cultures, (Kelsch el el. 1980).
Another supporting piece evidence comes from in vitro experi ments where the
importa nce of the Fe fragment of rabbit anti-mouse kappachain antibodies in prevent ing
the activation of murine B cells was studied. Intact rabbit anti-mouse kappa chain
antibod ies totally failed to induce tritiated thymidine incorporation over a three log l ~
concentratio n range. However, F(ab')2 fragments prepared from these same antibodies
led to a 'marked' incorporation of the radioacti ve label. A mixture of the intact antl-
kappa antibodies and the F(ab 'h fragments derived therefrom again prevented activation.
The researchers then went on to investigate Feinvolvement. Thi s idea was studied using
goat anti-moo se p chain ~fic antibodies which. even when intact . produced significant
8 cell activation. The stimulatory capacity could beincreased at any time tested by using
goat F(ab' h of anti·mou se". chain specific antibodies. 'Theresearchers concluded that the
immunoglobulin recep tor of murine B cells can serve as a triggering receptor provided
tl\at a negative signal mediated by cross-linkage involving the B cells Fc recepto r is
avoided (Tony and Schimpl.1980).
Accessory cell s may also be involved in suppression. "[Increased) .. . FeR·
mediated phagocytosi s of immune complexes may explain the requireme nt for FeR
binding, the antigen specificity and the non-epitope-specif ichy " (Heyman .l990b), As it
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stands. definitive data on the effect of accessory and B cell involvement i$ still needed.
however. the most plausible explanation. as of now, may lie in the combination o f the two
(Heyman , 1990b).
1.3.4. 10 Postulated Mechanisms
Thc literature conta ins a number of theories on the mechanism of IgO mediated
suppression. They can be summarized into three main theories. The first proposes that
suppression is the result of simple blocking of antige nic determinants by IgO antibodies.
These determinants are then hidden from immunocompetent cells (Hoffman and
Kappler .1978; Moller,1985). This mechanism is independent of the Fe compone nt of the
IgG antibody and is contradicted by the lite rature cited in this review which documents
the need for the Fe region. The second theory has been termed the ' periphera l theory'
(Ryder a nd Schwartz, 1969) and contends that the e limination of antige n is mediated by
increased phagocytosis of the IgO-antigen co mplexes. However, complement is known
to increase phagccytosia of immune complexes (Egwang and Befus, 1984) and the finding
that immunosuppression is independentof com plementactivation, therefo re, argues against
this theory. The third hypothesis, the ' central theory'. proposes that the immune
complexes cross-link Fe and antigen recepto rs on B cells thereby inducing an off signal
to the cells (Oberbamscheidt and Kelsch , 1978; O'Garra et al. 1987; Phillips and
Parker, 1985; Wiersma et at. 1989; Heyman , 1990b). The biochemical basis of the result
of the c rosslinking of Fe and antigen receptors is not completely understood. In manyce ll
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types, binding o f ligands to their receptors causes an early increase in freeintracellular
calcium and a rapid degradation of phosphatidylinosito l bisphosphate to inosito l
trisphosphateand I ,2-diacylglycerol (Berridge,1984) . Oneparticular studyexa minedthe
effectof crossJinking of surfaceimmunoglob ulinand R: receptorsand the degradation o f
phosphatidylinosilolbisphosphate and calcium cation concentta tion,two earlybioc hemical
responses in act ivated 8 cells. The resul ts indicated that the rapid degrnda tion of
phosphatidylinositol bisphosphate was abrogated but the increase in calciu m cation
concentration remained the same (Bijsterbosch and Klaus, 1985). The se find ings may
explain and/or provide a framework for understanding the mode o f action of the Fe
regionsof the IgG and the Fereceptors in regulating theact ivation o f Bcells in conce rt
wilhthei r antigen receptors (see Figure J) . It isquit e possible. however. that more than
one mechanism may be operating.
Figu re 3: Theoretical e xplanation oflgG m~d iat~d suppression. Cnlssllnklngof a cr iticalnumber
of Fe receptors and antigen rec eptors on the Bcel l ksu[L~ in a negative signal w hich cannot he
reversedby complement receptor hinding (Heyman. I99Oh).
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1.3.5 IgG Mediated Enhancement
Enhancement induced by passively administered 19G is thought to mimic the ac tion
o f natural IgG antibodies in a normal primary response and/or the action of antibodies
produ ced in a prima ry response on the secondary immune response (Van Roo ijen, 1990).
The complexi ty of the events associated with passive antibody administration is further
inc reased by theobservation that, under certain circumstances the primary re sponse itself
is en hanced rather than suppressed, wi th pretreat ment o f IgG ant ibody (Coulie and Van
Snick,1985; Parkus et sl. 1982; Wiersma etal. 1990; Wier sma, l 99 2), This is inco ntrast
to the pre vious repo rts describing experiments in wh ich pret reated IgG mediated
suppression. Unfort unately, to date, research and thus the literatu re do not conta in a
co mplete d eseription of this phenomenon. Antigen ch aracteristics such as particulate
ve rs us solub le, may play a role. for example, the same TNP·spedfi c IgG monoclonal
anti bodies that suppressed the antibody response to partic ulate TN p·SRBC have opposi te
e ffects on the response to TNP-KLH, a soluble antigen (Heyman, l99Ob). O ther fac tors
po stulated as being important are densi ty of epltope s, and the role of complement.
1.3. 5, I Response to Differing Antigens and Loca lization
In stu dying th e specific enhance ment of the antibody responses to prote inantigens
by IgG ami bodies in liw, Wiersma injected antibody be fore and after antigen had been
clea red from circula tion. and attempted to dete rmine if the antibod y acts by increasing
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antigen uptake (wlersma,t992). The response 10keyhole limpel haemocyanin (KLH) -
TNP antigen was enhanced bya T NP specific IgG monoclonal ;antibody. High and low
concentrationsof antibodyandantigenwereusedand all producing:an enhancedresponse.
Wiersma then tried other antigenssuchas BSA-TNP . OA-TNP, IT -TNP and diphtheria
toxoid(01) - TNP insimilar esperimenrs. Of these. only the response10 BSA·TNP was
enhanced by the specific IgO. In order 10 enhance the response 10 KLH·TNP and BSA-
TNP. the IgO antibodyhad 10 be injected while the antigen W lU circulating in the blood
stream. These data suggested that IgG mediated stimulation acts by concentrating
circulating antigen into the secondary lymphoid organs (Wiersma,1992). thereby giving
a more efficient presentation of antigen 10 the B cel ls.
1.3.5.2 Density
Wiersma (1992) fo und that IgOantibody caused optimumenhancement when it
recognizeda low number of epilopes on the administeredantigen. Thus, as seen before.
density of epitopes also seemsto have an impacton the primary response.
1.3.5.3 Roleof Complement
The role of complement also was investigated by various researchers. Wiersma
et sl. (1990) examined the importanceof complemen t to IgO mediated enhancement by
immunizing mice withTNP -KLHafter injectingthem either witha complement-activating
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TNP-specific monoclo nal lgG antibody, or witha variant of this antibody which was non-
complement activating . Both the nonnal and mutant antibodies en hanced the anti-KLH
response, although the normal antibody gave a stronger enhancement. Thus, indica ting
thai the classica l pathway is likely to be of some importan ce, In another experimen t, a
complement-activating IgGantibody enhanced the antibody response in mice depleted of
C3 by treatment with cobra venom factor. A na turally occurring IgG non-complem ent
activating 'r'N p-specific antibody, in the same expe riment , wasalso able 10 enhance the
response to TNP-BSA. Thesefindingsdemonstrat e thatthe ability 10activate complement
is not an abso lute requiremenl for the ability to e nhance (Wiersma et a1. 1990), It has
been earlier shown that the haemolytic capacity of antibodies mainly requires classical
pathway C activat ion, indicating that the classical pathway is the main means by where
IgO activates (Bindon et et. 1988), The data demonstra ting that C-activated IgO is an
equally efficient enhancer of the antibody response in normal mice as in mice depleted of
their C3, also suggests thai the alternative pathway is unlikely to playa role. Although
these mice ha ve low traces of C3 in circulation it is not be lieved that there is enough for
completely no rmal en hancement (Wiersma et st. 1990), Thus, from these studies the
requirement to activate complement is not essen tial to the IgG mediated enhancement
suggesting th at there may be another cooperating factor or factors involved in the
enhancement process. Interestingly, these studies do not address C4b, since it also b inds
C3b receptors and woul d beactivated in the absence of C3,
1.:15.4 Mechanisms of IgG Mediated E nhancement
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Alth ough the inve stigators who proposed the vari ous mec hanisms have
d emonstra ted that c omplem ent may not benecessary for enhance ment, involvement of
comp leme nt is still a major part of the speculation. It maybe the antige n ch.1ractcri stics,
such as size, and the den sity of epitepes recognized by the IgG antibody that might
influence the inte ra ction betweenthe immunecomplexes, complement receptors and tile
Fe receptors (Wiersma, 1992 ). As p reviously mentioned . evidence io-da te implics tbal
IgG suppression acts bycros s-linking membrane imm unoglobu lin and Fc recepto r (type
two) on the Bcell , with a c ritical size of the antigen needed fo r obtain ing an inh ibitory
cro ss-link (Heyman , I990b) . Some researchers favour a model o f IgO medimed
en hancement where IgG-2.nt igen com plexes a re cap tured by follicular dendrit ic cells.
which carry FcR as well as complement rece ptors (He inen ct s l. 1985 ; Wiersma cl af.
1990). Both the abi lity of tbe IgG ant ibody to bind to the FeR . as well as the ab ility to
activate complement art esse ntial prope rties in this model. This model wou ld also elpbin
why non-complement activati ngmonoclonal (gG antibodi es ga ve slightly less stimu bt ion
as compared to complement activating IgO monoclo nal antibodies (Ca rter tf et. 1988).
B cells may also be involved . Enhancement may be in pari due to the stimulation of B
cells by com plement fragments via their co m plemen t recepto rs (Melchers tf al. 1985).
Heyman (I99Ob) has proposed that the enha ncing e ffect depe nds on the ability of IgG
an tibody to bind both fe R andoom plemcnt rece ptors (sec Figure 4), thus causing e fficient
localization on folli cular den dritic cell s, whic h cany both types of recep tors. In add ition
to this, the complexes could stimulate Bcells directly via comp lement receptors on these
cells .
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Figure4 : Theoretica l expla nation of IgGmediatedenhancement. IgG soluble antigen
complete s cannot inducethe critical numbero f Fereceptor' antigenreceptor crosslinking
on tileB cell surface toinducea negativesignal (Hey man,199Ob).
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1.3.6 Summary
1.3.6. 1 IBM Med iated Enhancement
Theenhancing e ffect on the primary immune respo nse by pretrea tment with
specific IgM antibody has been well doc umented. The effect can be demonstrated with
both particulate and soluble ant igens. With respect to speci ficity. the response can be
described as antigen specific but not epitope specific. A time fac tor exists, such that
administration of specific ISM antibody one to two hours prior to antigen results in
optimal enhancement. Ig M antibody is to able enhance antigen localization in the spleen.
In vim demonst ration o f enhancement was not replicated in vitro. In fact. in vi tro
experiments resulted in a suppression o f the primary respon se. ISM enhancement is
further dependent upon T cellhelp anduponcomplement factors, speci fically uose :lCting
before 0 . Increased antigen localization on follicular dendritic cells by complement
receptors is believed to playa ro le. Themost plaus ible cellular mechanism is stimulation
of B cells via crosslinking o f complement and antigen receptors by IgM • antigen
complexes,
1.3.6.2 IgO Me diated Suppress ion
It has been clea rly shown that mice pretreated with specific IgG antibody eahibit
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suppressed levels of both IgG and IgM antibody levels in the primary response. IgO
antibodies can specifically suppress the response against both particulate and soluble
antigens. This suppression is non-epitopc specific but is antigen specific. IgO antibodies
binding to one epitape suppress the response to all epitopes of that same antigen. All
subclasses of IgG can be suppressive. Other factors affecting suppression include the
affinity of the antibody and the number of cpitopes recognized by an administered IgG
preparation; increases in either have the effect ofa greater suppression. F(ab') l fragments
of specific IgO antibody were found to be significantly less suppressive compared to
complete antibody. Thus, Fe receptors are probably required for suppression. In vitro
experiments t.avc also been able to demonstrate IgG induced suppression. Erperiments
have also shown that the suppression by IgG is not dependent upon the presence of T cells
nor is complement needed. T helper cell activity is unaffected in antibody suppressed
mice. Suppression of the primary response is also extended to the secondary response,
shown by the inhibited induction of memory. Of the proposed mechanisms for IgG
mediated suppression. the central theory seems to fit best with the above findings. This
theory contends that immune complexes crosslink the Fc and antigen receptors on the B
cell thereby delivering a negative signal to the celt which cannot be reversed or overcome
by binding of complement receptors.
1.J.6 .3 IgG Mediated Enhancement
The field of modulation of immune responses by pre-existing antibody has been
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considerably complicated by the finding, incertainexperiments with soluble ;lntittcn, that
specificIgGcan sometimesenhance theresponse. This contradictsan earlierconcept that
IgMenhanced, while IgGsuppressed the immune response. Althoughsomeexperiments
have demcnstn-cd that complement appears not to be important to IgG-mcdi"tcd
enhancement. paradoxically, the proposed mechanisms of the IgG mediated enhancement
viewcomplement as playing a vital role. The most widely accepted mechanism is that
this suppression results fromthe antibody-antigen complexesnot being able to induce the
threshold number of Fe and antigen receptor crossfinks on the surfaceof the B cell.
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CHAPTE R 2
AIMS AND OBJECT IVES
2, I Research Group Objectives
One overall objective of our research group is to make mouse monoclonal
antibodies to polymorphic determinants on HLA·DP molecules. As this is by no means
easy or straightforward we have been looking for ways to improve the creation of
hybridomas from immunised mice. Among several projects with this aim is the present
one, namely to see if antibody enhancement can be used to improve the hybridoma
technology and to explore the possibility that pre-existing IgG produced, for example, by
repeated immunisations might actually reduce the subsequent immune response to class
II HLA molecules.
2.2 Specific Thesis Objectives
The particular aims of the experiments. reported in this thesis, were :
I) To determine if the same phenomena are observed when using either human B cells
or mouse fibroblasts transfectcd with HLA·DP , as antigens; namely that a specific IgM
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antibody could enhance and conversely, an IgG antibody could suppress, the primary
immune response 10 HLA-DP antigens.
2) To study the feasibility of using IgM enhancement to improve the yield of HLA·I)P
and HI .A-OR specific hybridomas from mice by decreasing the time necessary 10 produce
hybridomas or by increasing the number o f hybrido mas specific for HLA-DP and HI.A-
DR.
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CHAPTER 3
MATERIALS AND METHODS
3. 1 Animals
Balb/c and C3H mice obtained from the breeding facilities of Charles River
Canada, Inc. (188 Lasalle, St-Constant, Quebec, Canada) and FI hybrid mice resulting
fmm a cross between Balb/c m~!,'s and C3H females were used. The Fl hybrid mice
were bred by the Animal Care Unit personnel at the Health Sciences Centre. Memorial
University of Newfoundland. All animals were approximately 6-8 week old females
unless otherwise stated. The mice were housed in standard clear plastic cages and
allowed food and water at will. Animals were kept at the Animal Care facility in the
Health Sciences Centre.
3,2 Antibodies
The two primary monoclonal antibodies used to manipulate the prc-existing
antibody levels were NFLD. M65C3 and NFLD,M68CII CIt Monoclonal DPI39BD9 was
used as a IgM non-specific antibody. NFLD,M67 was used in the assays as a positive
control.
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Table I : Summary of Monoclonal Antibodies Used With Respect to Class and
Specificity
ANTIBODY ISOTY PE SPEC IFICITY
NF LD.M65 C3 10M IILA-DP. U""lIline. - n:,,, 1I<
wilha ncpilt>re 1i\Ulldtln . 1In t'
IYr<:s.l'",t ymll'l'hi<:wilh
trtln~Ii.'eI.'1l fihrul>lllsls
NFLD. M68C II CB IgOll • fIIA -OP. B "clI linc~- !'Cud.•
w;lhll ncl';l<lf'I'f"unJtlll . lI l>1'
lyr""'"nU Irlln~ti.'eIL'llIi",, ~lIaM L'ell
line.
DP I39BD9 10M MIlu......llnl i"t1dy . <It "'. "' ~ "inllt"
hlllTUln l llA
NF LD. M67 IgO I III.A ·DP. B Locll lillt:s - reIId~
wilbll ncl'iblf'Cfuu nll,1(1l1l1 01 '
IYl"l" lInJtn n1lf""I...J fihr.. lll ",bI
Mon oclonal antibodies were secreted by the hybrid cells into Dulbecco' s Modified
Eagle Medium (DME M) containing , 10% heat inactivated Feta l Bovine Serum (P BS)
supplemented with I % sodium pyruvate, 1% L-Glutamine, I% Penicillin and
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Streptomyci n, (Gibco BRl, Canadian Life Tec hnologies, Burling ton, Ontario, Canada) .
All hyb rid cell lines wcre grown at 37°C, in a 5% COl incuba tor. T hese monoclonals
were ob tained from, and have been examin ed for their respective specificities pre viously
in this laboratory,
3.3 Ant ibody Purification
IgM and IgO hybridoma cell lines were allowed to overgrow in approp riate media
for 34 wee ks. The antibody containingmedia were first centri fuged at 3400 rpm for 30
minutes and then conce ntra ted at 4(1Cwith an Amicon Ultrafiltration Cell, Model 402
(Arnicon Inc, USA).
3.3. 1 IgM Purificat ion
In the case of the Ig M antibod ies, the concent rated antibody conta ining culture
supernatant was ap plied to an Anti-Mouse IBM (I{ cha in specific) • Agarose co lumn and
pu rified accordingly (Sigma Chemica l Compa ny, USA). The co lumn was equili b rated in
a.DlM sodium phosphate buffer, pH 7.2 containing 0.5M sodium chlo ride. The
supernatant was applied slowly and re-cycled at least three times. T he colu mn was
stripped by washing with 0 . 1M glyci ne, O.15M sodium chloride , pH 2.4. One rnilhlitre
fractions were co llected in 1ml of Tris·HC l buffer , pH 9.0 , on ice; this procedure
immedia tely re-adju sts the collected fractio ns to a neutral pH . The Bio-Rad Econo
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Syste m, Model ES-I (Bio-Rad, USA) was used in order 10 monitor column washing and
the eluted frac tions for protei n. Fractions were then poo led and measured lor protein by
a Ou Series 60 Beckman Spectrophotomete r, Nucleic Acid Sort-Puc Module (Beckman
Instruments, USA). The sample was then dialysed llSi n~ SPECT RA/POR
Molecularporo us Membrane Tubing 2 (molecular weight cut off : 1.2000 . 140( 0)
(Spectru m,USA) agains t O.15M PBS at 4''C for 24 hours, with frequent changes o f buffer.
The samples were again measured for protein as before and concentrated with 01
Cen triprep- IO Concen trator (Amicon Inc" USA), filtered sterile with a 22101m Milh porc
filte r uni t (Millex-GS, Millipore , USA) and agai n measured for protein. The purified
antibody was stored sterile at4nC, After eluting, the column was re-cquilibrmed as before
and stored with 0.05% sodium azide in an equi librating buffer, at 4nC.
3.3 .2 IgG Purification
The IgG antibod ies were purified with the usc of the Affi-Gcl Protein A MAPS
II Kit [Bic-Ra d, USA). Binding buffer and elu tion buffers were prepared using Am -Gel
Protein A MA PS II Binding Buffer and Affi-Gel Protein A MAPS II Elution Buffer (llio-
Rad, USA). The sample was applied to the co lumn, diluted one to one with Binding
Buffer and re-cycled at least 3 times. After elution of the antibody, the co lumn was
wa shed with Affi-Gel Protein A MAPS II Regencrat ion Buffer and stored in 0 .05 %
sodium azide in O.I SM PBS at 4°C. The Bio-Rad Econo Syste m, Model F~') ·J (Bio-Rad,
USA) was used in orde r to monitor the eluted fractions for protein and to ensure the
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column washing was complete. Again Iml samples were collected in I ml ofTris-HCL
buffer. pH 9.0. on ice. The protein containing fractions were pooled and measured for
protein by a Du Series 60 Beckman Spectrophotometer . Nucleic Acid Soft-Pee Module
(Beckman Instruments, USA). The samples were then dialysed using SPECTRA/PQR
Molecularporous Membrane Tubing 2 (molecular weight cut off : 12000-14000)
(Spectrum,USA) in 0.15M PBS over 24 hours with frequent changes of buffer. The
protein content again was mcasurcd before and after concentrating the sample via
Centriprep- IO Concentrator (Amicon Inc.. USA). The sample was then fillered sterile
with a 22prn Millcporc (Millex-Gs, Millepore, USA) tiller unit and measured for protein.
The sterile purified antibody was thcn stored at 4°C. (Sec Introduction Section 1.3.4 .2
Ability of various subclasses to suppress.)
3.4 SDS-Gel Electrophoresis
Purified samples of IgM and IgG antibodies were examined and compared through
SDS-PAGE in a vertical slab-mini-gel apparatus . Specifically the Bio-Rad Mini-Protean
II and the Bio-ROO Model 20012.0 Power Supply were used for all gels. The gels were
nm at constant voltage 165V.
The buffers used for electrophoresis were as follows :
For the running Gel I.5 M Tris, pH 8.8
For the stacking Gel : tOM Tris. pH 6.8
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211. Sample Buffer :
0.12M Tris pH 6.8
4% SDS
20% Glycerol
Three drops of a 0.0 1% Bromophenol blue solution
10% 2-Mercaptoethanol
The gels used for electrophoresis were as follows ::
12% Running Gel :
dist. water 3.3 mls
30% Bis-acrylamide 4.0 mls
I.:5M Tris (pHS.8) 2.5 mls
10% Ammonium persulfate 100p.1
10% SOS 100p,1
Temed (N, N, N' • tctramethylcthylencdiamine)4.0 p,l
Butanol saturated water was used to layer thc top during the setting lime PO minutes) of
the running gel. This was made by mixing50 ml of butanol with.5 ml of distilled water.
This allowed a very distinct interface to develop.
Stacking Gel :
dist. water 3.4 ml s
30% Bis-acrylamide0.83 ml
I.OM Tl is (pH6.8) 0.63 ml
10% SOS 0.05 ml
10% Ammonium persulfate 0.05 ml
Temed 5.0 p,1
This gel was allowed 10 set for 20 minutes.
Protein Stains :
Protein was stained with Cocmassie Brilliant Blue. This stain consisted of :
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0.8g Coomassie Blue (Brilliant Blue R)
1000 mls Methanol
140 mls Glacial acetic acid
This was then made up to 2 lures with distilled water, filter.
The destain consisted of :
600 mls Methanol
140 mls Glacial acetic acid
1260 mls distilled water
After pouring the running gel and stacking gel, the samples were mixed with the sample
buffer and boiled for 5 minutes. The samples were loaded to the appropriate wells (such
that 5~g of protein of the sample was added per lane) and the gel was run. The gel was
then removed from the Bio-Rad Mini-Protean II apparatus and placed in a shallow dish
for staining. Gels were stained for at least 3 hours and then destained until most of the
background stain of the gel was removed. For all gels a molecular weight marker
containing hen egg white lysozyme 14400 kD, soybean trypsin inhibitor 215oo kD, bovine
carbonic anhydrase 31(X)() kD, hen egg white ovalbumin 42699 kD, BSA 66200 ltD and
rabbit muscle phosphorylase b 97400 kD was used (Bio Rad, SDS·PAGE, Molecular
Weight Standards - Low, Bio-Rad Laboratories, USA).
3.5 Antigens for the In \.7m Experiments
Human B cells used were the RAJI cell line and the cell line 2.4 .93. The Raji cell
line was obtained from the 9'" International Histocompatibility Workshop. The 2.4 .93 cell
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line was obtained from Dr. Tom Cotner. University of Washington . School of Medicine.
Seattle , Washington , USA. 2.4 .93 has a single wild copy offhe L2P-lgenc and a single
copy of HLA-D PtIl -0401 and HLA-DPal·OIOI. Both these line s were maintained in
RPMI 1640 supplemented with 10% FBS (heat inacti vated) , I% Sodium Pyruvate, 1%
L-Glutamine, I % Penicill in and Streptomycin. (Gibco BRL, Canad ian li fe Technologies.
Burlington. O ntario. Canada).
A mouse fibroblast transfected with Human HLA-DP genes were used. specifically
L25.4, The L25 .4 cell line was obtained from Robert Karr , Department of Immunology
and Infectious Diseases. Monsanto Co.lAA4C , SI. Louis. Missouri . USA. The II ·
International Histocompatibility Workshop numbe r of this cell line is 8305. l 1te cell l ine
was maintained in DMEM supplemented with 10% FBS (heat inactivated). I % Sodium
Pyruvate, 1% L-Glutamine, I% Penicillin and Streptomycin. (Gibcc BRL. Canadian
Life Technologies, Burlington. Ontario. Canada ).
The B Cell and the tran sfccted mouse fibrob last lines were maintained at 37"C in
a 5% CO! incubator .
3.5 .1 HLA Ty ping of Raji Cell li ne
ALA typing of Class II; HlA-DR. DQ and HLA C lass I; A. D.C was performed
in separate 72 well, po lystyrene, non-sterile, mini trays with lids (N unc. Intermed Nunc. ,
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Inc., USA). Thcse com plement dependent cytotoxic (CDC) typi ng trays were supplied
by the Canad ian Red Cross Society (National O ffice, HLA secti on . Manufactu ring and
Development. 1800 Aha Vista Drive, Otta wa, Ontario. Can ada. K IG 4JS) . HLA typ ing
of Class II; HLA-DP was typedwith theaid of a panel of monoclonal antibodies produced
in this labor.iltory that were specific for knownepitopes on HLA·DP . This panel consisted
of NFLD.M5S, NFLD.M60. NFLD.M66, NA. D.M73, NFLD.M77, NFLD.M10i .
NFLD.MI06, NFLD.MI II . NFLD.MI12. NFLD.MI 14, NFLD.MIIS. NFLD.MlI 6,
NFLD.MI17, NFLD.MI 18, NFLD.MI19. NFLD.MI20, OGPM and MYE90l. Th ese
antibodies were tested against the Raj i cell line by a live cell ELISA (CELlSA) and tlow
cytometry.
Typing with the cue plates was performed as follows :
I) 24 hours prior to testing, the RAJI cell line was fed. maintaining a cell concentration
of 3 II lOS cellsl ml. On the day of testing, the celts we re counted using a
heemccyto merer. A total of appre ximarely 3 II 10' cells /well was used. 1bc cells were
then centrifuged at 1500 RPM for 10 minutes at room temperatu re , washed with RPMI
1640 supplemented with 10% FBS (heat inactivated). 1% Sodium Pyruvate. 1% L-
Glutamine, I % Penicilli n and Streptomycin , (Gibco BRL, Canadian Life Technologies,
Burlington. Ontario , Canada), and resuspended in the correct volume of the same
mediu m.
2) With the aid of a lambda Jet (Model U-60 n2. One Lambd a. Los Angeles, USA) 1 ~1
o f the cell suspe nsion was added to each wen . such that the required 3 II 101 cells were
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dispensed per well.
3) The plates were incubated at room temperature for I hour.
4) Complement was then added. Co mplement used was Low-Tox-H Rabbit complement,
stored at -7C1'C and thawed on ice (Cedar Lane Laboratories Limited, Hornby. Ontario.
Canada). 300 /AI o f complement per plate was required (5 pI of complement/well). This
Complement was used at a dil ution o f I in 3 : 2 mts o f complement + 4 mlsof diluent.
Diluent consisted of 2 mls of RPMI and 2 mls of heat inactivated fetal bovine serum
(Gibco BRL. Canadian Life Technologies, Burlington, Ontario . Canada).
5) Plates were incubated at room temperature tor I hour .
6) 5fll of Eosin stain (Sigma) was added.
7) The cells were fixed in S#oi1 of (filtered) Formalin.
8) Plates were allowed to incubate in the fridge for 1-2 hours.
9) A cover slip was placed over the entire plate and then read/scored wit h aid of Lambda
Scan Plus II (One Lambda, Los Angeles, USA).
3.6 Administration o f Antibody and Antigen
Antibody and antigen were both given intravenously via the tail veins. The
animals were placed in a warm roo m (22°C ~ 25°C) for approximately 30 minutes prior
to any manipulation. The mice were then lightly anesthet ized with ether and placed in a
mouse restrainer. To dilate the ve ins further , warm water was then run over the rail.
The correc t concentration and volume of antibody or antigen was then administered
48
intravenously.
Prior to injection, cells were washed 4 times in sterile 0. 1SM PBS at 500 8, for
10 minutes at approxi mately 2o.2s-c. Total resuspended volumes varied from 500-700,1&1.
The cells were injected immediately after washing. In some cases 100,1&1 of a Heparin-
Sod ium injection (Allen and Hanburys, AGlaxo Canada Limited Company , Canada) was
administered intraperitoneally, 15-30 minutes prior to the antigen . This was done with
mice receiving (or in excess of) 3.5 x I()'! fibroblast cells. The heparin relieved the
degree and the effects of clumping in vivo that the fibroblasts caused when given in large
3.7 Blood Collection
The animals were placed in a warm roo m (23OC - 2JOC) for approximately 30
minutes prior to any manipulation. To ob tain blood , the mouse was first lighlly
anee stbetized with ether , and placed in a plastic mouse restrainer. The tip of the tail then
was cur and approximately 100pl of blood were collected into capped polystyrere
microcentrifuge tubes.
3 .8 Serum Collection and Storage
Blood collected from the mice was first allowed to c101, approx imately 30 minutes,
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at room temperature, and then centrifuged for 30 seconds in a Beckman Microfugc B.
11,000 g. The serum then was transferred into capped polystyrene microcemrifuge tubes
and frozen for storage.
3.9 Measure ment of Antibody Levels
To measure the titre of antibodies to HLA-DP molecules in mouse sera, the
Ce llular Enzyme Linked Irnmunosorbant ASlklY (CEUSA) was used. The mouse serum
was added to wells of a microtitre plate and allowed to bind to the selected cells. Next
an enzyme linked anti-immunoglobulin was reacted with the mouse antibody-target
com plex. This enzyme-linked anti-immunoglobulin was detected by add itionot Opuand
substrate. The degree of colour change thai results is in direct proportion to the amount
of specific antibody contained in the serum. This was quantified by the use of a
spectrophotometer.
3.9.1 Modified Procedure for the CELISA involving Human B Cells
This methodology was previously developed in this laboratory prior to my
experiments and has been slightly modified to fil the experiments outlined in this thesis.
For this assay flexible Microtiter Plates U-bottom 96-well Poly vinyl chloride microplates
(PVC) and LimbrolTitertek microtitra tion 96 flat bottom multi-well plates were used.
The assay was carried out with the following reagents and in the following manner:
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Reagents:
l) 0.15 M phosphate buffered saline. PBS, pH 7.4.
2) A. 2~ Bovine serum albumin (BSA), (Sigma) in a.15M PBS.
B. 0.5% BSA in a. ISM PBS
3) I mg o f Poly·l...Lysine (PLL), (Sigma) in l OOml of PBS and stored at 4OC.
4) Coojugate (2-' anlibody)
A. Fragments of peroxidase- labelled affinity purified (Fab' 2) goat anti -mouse
immunoglobulin (heavy and light chains), obtained from the Jackson Immune-Research
(USA) were used. The optimum dilution of the conjugate was predetermined and a
dil ution of 112500 in 2~ BSA·PBS was used.
B. Horseradish peroxidase (HRP) • labelled goat anti-mouse IgM (heavy chain
specific), (Southern Biotechnology Associates, Inc•• USA) used at a I in 2000 dilution,
3 S previously determined.
C. Horseradish peroxidase (HRP) • labelled goat anti-mouse tgG (heavy chain
specific). (Southem Biotechnology Associates, Inc., USA) used at a 1 in 2000 dilution.
as prevK>usly dctermined.
5) Phosphatc citratc buffer , pH 5.a
A. a. I M Citric acid
B. a.2M Sodium phosphate
Thi s buffer consisted of 4.9 ml o f the Ci tric Acid. 5. 1 ml of the Phosphate and 10 ml
distilled water, pH was checked 10 be approximately 5.1. If less than 5 the buffer was
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adjusted with phosphate and if greater than 5.1 it was adjusted with citric acid.
6) Substrate
Fresh substrate was made prior to use. For each plate 10 ml of substrate was required.
The substrate consisted of 4 mgof orthophenylenediamine (OPO) (Sigma) dissolved in 10
rnl phosphate citrate buffer. When completely dissolved 4 ~ l of 30% H10 1was added.
7) 2.5N H2S0 4
Target cells :
I) 2.5 x 104 cells/well (2.5 x 10'"cells/plate) were used nt 9O%viability and in log growth
phase.
2) The cells were centrifuged for 10 minutes at 400 g and washed once in 0.5% USA·
PBS.
The procedure for the CELISA involving Human B Cells is as follows;
I) The peripheral wells of the plates were not used and duplicate wells were used for all
sera tested. The sera were diluted in doubling dilutions from I in 50 to 1 in 1600.
Blanks were run on each plate consisting of 10% FRS, as were appropriate positive und
negative controls.
2) 10 ~l target cells/well to PCV plates were added.
3) 10 ftllwell diluted antibody or supernatant were added and then milled.
4) The cells were then incubated for I hour at room temperature.
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:oi) 100 pi/well ofO.S~ BSA was then added and the cells centri fuged at approxi mately
200 g for 5 minutes at SOC.
6) TIw: supernatant was then flicked off and the plates drained on pape r towel after wh ich
the cells wen: resuspended.
7) The cells were washed tw o more times with ISO III 0.5% BSA-PBSlwell and
centrifuged as before .
8) SOpI/well of conj ugate was added.
9) The plate s were a llowed to incubate 1 hour at room temperature .
10) Limbro/Tuenek microtitration plates werecoated with 7S/II PLL for at lea st 112 hour
and nicked off.
I I) The PVC plates were washed four time s as before. For the first wash 7S /11 of wash
solution was added and the pla tes spun.
12) The cell s were resuspended. Th e U-bo ttom PCV plates were snapped onto
limbrotTite rtek microt itration plates.
13) 100 /II of PBSwa s then added . Hole s were punched in the cen tre of eac h well using
an I 8 gauge needle.
14) The plate s were cent rifuged at 200 g for 7 m inutcs.
15) The U-boltom plates were removed a nd the supernatan t nicked off the
Limb rolTitenc k mic rotitration plate.
16) 100 /II/well of substrate was added.
17) T he plates were incubated in the dark for 1/2 hour at room temperat ure .
[8 ) 50 /A I o f H,sO.twell was add ed.
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19) The plates were then read in a Multiscan Spectrophotometer (Bio-Rad Model JSSO
Microplate Reader).
3.9 .2 Procedure for CELISA involving Fibroblasts
A modificat ion of the afore mentioned CELISA was used to detect the relative
amount of antibody in serum when using the transfected fibroblasts as the antigen. This
procedure takes advantage of the "stickiness" of the fibroblast cells.
Reagents :
I) O.15M PBS as described earlier.
2) 0.5% & 2% BSA as descri bed earl ier.
3) 0.05% Twecn-20 (BOH lnc., Canada) in 0. 15M PBS.
4) Conjuga te as described earlier.
5) Phospha te-Citrate Buffer as described earlier.
6) Substrate as described earlier.
7) 2.5N HzSO.
Ta rget Ce lls :
1) Were greater than 90% viable and in log phase.
2) 5.0 x l <f cells/well in 100 po l/well of 10% FRS DMEM were used.
The procedure for the fibroblast CELISA is as follows:
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I) The peripheral wells of the96 PCV plates were not used. Protocols for all pla tes prio r
10 the expe riment were made. The serawe re diluted in doubling dilut ions from I in SO
10I in 1600. BIaJ1ks wen: run on each plate consisting of 10~ FRS, as wereappropri a te
positive and negative con trols.
2) The transfectan ts wen: plated in sterile, 96 multi-well flat-bot:tom cul ture plates andleft
ovemig ht at 3'1'C in a S% CO, incubator .
3) The plates were then flicked.
4) Washed once with O.OS% PBS-Tween. Added 2.5lLl/well of the appropri ate ant ibody
5) Incuba ted at room temperat ure for appro ximately I hour.
6) Flicked plate and washed four times as be fore. Added 50 Ill/well mouse co nj ugate.
7) Flicked plate and washed four limes. Added 100 Ill/well substra te. Incu b ated 30
minutes in the da rk.
8) Added 50 Jl.Vwell2.SN H:S0 •.
9) Plates wert read in a Multiscan Spectrophotometer (Bio-Rad Model 3S50 M icroplate
Reade r).
3. 10 "l ow Cyto metry
For these experiments a Becton Dicki nson FACS~"" flow cyto meter was used
to analyze all samples.
Reagents :
I) Azide Buffer (FACS Buffer)
0.01 % sodium azide & 0.001 % FBS (heal inactivated). (Gibeo BRL, Canadian Life
Technologies, Burlington,Ontario, Canada) in 1L ofO.15M PBS. Thisbu ffer was kept
at ap proximately4°C at all times.
2) Fluorescent Antibody
A. R-Phycoerthrin-Affini Pure F{ab'h fragment goat anti -mouse IgM, It chain
specific with minimal cross-reaction10human,bov ineand horseserumproteins, (Jackson
Immuno Research, Laboratories, Inc., USA). The optimumdilution wasp redetermined
and a dilution of I in 20 was used.
B. R- Phycoerthrin conjugated Affini Pure F(ab' h fragment goatami-mouse IgO,
Fc fragment specific with minimal cross-reaction 10hu man, bovine and horse seru m
proteins, (Jackson Immune Research, Laboratories, lnc., USA). Theoptimum dilution
was predeterminedand a dilution of I in 20 was used.
3) 1% Parafonnaldehyde in 0.15M PBS
Target Cells:
I) We re used atleast 2.5 x 101 cells/tube, a19O% 'liable andin log growth phase.
The procedure for FACS analysis is as follows :
I) The correct number ofcells were placed in separate polystyrene culture tubes.
2) T he cells were wa shedonce with Imlflube of Azide Buffer and centrifuged fo r 5
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minutes at 300 g. at appro"imately 8"C.
3} The supernatant wa s then pouredoff and the pellet resuspended.
4) 20".1of lest antibody wasadded. Making sure that the antibody concentra tionwas 30-
40 ",glml. The cells were men placed at 4-c for JO.4O minutes.
~) TIle cells were then washed 2 times as before.
6) 20 ".1of Ileorescent antibody was then added to the cell s.
7} Th e cells were then placedat 4"<:(in the dark) for 30 minutes.
8) Th e cells were then washed 2 limes as before.
9) T he pellet was the resuspended in 150 ".1of 1% Paraformaldehyde-Q.15M PBS.
10) Florescence was measured usinga Becton Dickinson FACStarf.....
3. 11 Creation of HybriJomas
These methods were previously developed in thi! laboratory prior to my
experiments and have beenmodified for theexperi ments outlined in this thes is. Fo r all
fusion experiments F I hybrid mice were used.
3. 11.1 Preparationof Reagents and Med ia
A. Alkaline Media
To 50 mlof DMEM 1 drop of 5N NAOH was added. The pHwas checked and adjusted,
if nece",,-ry. to 7.8 • 8.0. filtered steri le with a 22 ".m Mi1Iepore filler unit (MiIlel-
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GS,Mille pore, USA ), and placed a t -,"PC.
B. Polyethylene Glycol (PEG)
I gram of PEG was placed in small capped glass via l and set in a beaker with water in
the bottom and autoc laved. I mlof the Alkal ine Medi a wasthen added per vial. resuhing
in a final concen tration of 50% wt./vo l. PEG. Samples were stored at J7"C. An extra
vial of PEG was a lways pre pared for every fusion.
C. Hypo xanthine , Aminopterin a nd Thymidine (HA T) Med ium
A stock solution of looX H AT was prepared in bulk. ahquoted and stored U1 -20oC. The
lOOX HAT was prepared by disso lving 136 mg o f hypoxanthine (Sigma), 38 rng o f
thymidine (Sigma) and 1.76 mgof aminopte rin (Sigma ) in 80 mls of sterile HID. adding
a few drops of SN NaGH to aid in dissolving , The so lution was litrated wiih IN HCI 10
pH 7.0, filtered sterile with a 22 #tm Millipcr e liIte r unit (MilIclt-GS. Millipore, USA).
and frozen in appropriate a liquots.
D, HT Media
This med ium was prepared exactly the same as ror the HAT media with the exclusion of
the aminopterin.
3.11 .2 Pre paring Spleens for Fusions
I) Mice we re injected with the appropria te a mount of purified NFLD .M65C3
intravenously.
2) Following an incuba tion period of 1-2 hours the antige n, Raji cell. was also injected
intrave nously .
3) The anima ls werea llowed 10 remain for 3 day s.
4) The mice were then sacrificed by cervical d islocation and the spleens removed
aseptica lly.
S) The spleens were placed in a sterile. polystyren e , disposable , l 00x 20mm style tissu e
culture dish (Polar Plas tics LTD" Quebec, Canada) containing 10 mls of serum free
DMEM medium containing I % Penicillin and Streptomycin (PIS) . The spleens were
teased apart usin g bent. sterile 21 gauge needles I In long (Preci sionGlide, Becton
Dickinson, USA) mounted on disposab le, sterile Xc syri nges (Becton Dickinson and
Company, USA) until most of the celts were release d . Breaking upany remaining clum ps
of rema ining cells was accomplished by gently p ipet ting back and forth the spleen cell
suspension within thec ultu re dish .
6) The suspension of cell s was then tran sfem:d 10 a sterile centrifug e tube. The tissue
culture dish was rinsed with 3·5 mlsof media, ad d ing this to the centrifug e tube.
7) The suspension was allowed 10 stand for loS minutes pe rmitting the: larger pieces 10
senle to thebottom,
8) The supern atant wa s then pipetted off from the sedi ment and placed in anothe r
centrifuge tube .
9) Splee n cells were co unted by a making a 1110 d ilution with 3% acetic acid , using a
haemocytometer.
lO) The spleens wi thin the same treatment groups were then poo led.
I I ) The pooled splee n suspension was then washed once in PIS DMEM.
3. 11.3 T Ce ll Depletion of the Spleen Suspension
1) T cells were de pi cted by usinga ntibody coated magnetic beads, Dynabcads M-450
coated with sheep anti-rat IgG (Prod uct No. 110.08. D ynal, Dynal Inc.• U.S.A). l11C
beads were additionally coate d at this laborato ry with T IBI04. a rat anti-mouse T cell
antibody. The TIBI04 cell line was obtained from A merican Type Culture Collection
(Rockville, U,S.A). A ratio of splcen celts to metallic beads of I : 3 was used. The
beads and cells were added together in 5% FBS DMEM media. total volumeof 6~7 mls
in 15 mls sterile ce n trifuge tubes.
2) The ce ll-metallic bead mixture was then rotated on an Adams Nutatcr (Becton
Dickinson and Com pany, U.S .A) for 15 minutes at room temperature.
3) Thecentrifuge tu bes were thenplaced in a magnetic holder. Dynal MPC-I Magnetic
Particle Concentrator (Product No.12001, Dynal , Dynal Inc. , U.S.A) for 1-2 minutes
after which the T ce ll deple ted cell suspension wasdeca nted of f intoa centrifuge tube.
whilst holdi ng the 15 mls tube in the magnetic holder.
4) The metallic beads were washed with 10 mls of serum-free l>MEM medium
co ntaining PISand th e remaining unbound popu lation of cellsagain added to the existing
collection.
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5) TheT cell deple ted samples were then wa shed with PISDMEM by centrifuging for
8 minutes at 1500 RPM.
6) Cells were then counted as before .
3. I 1.4 Preparation of Myeloma Cells for Fusio n
Th e myelo ma cell lin e used for all fu sions was Sp2/0 obtained from R obert
Weaver, Van couver . Cells weregrowni n RPMI1640su pplemen ted with 10%FBS (beat
inactivated ), I% Sodium Pyruv ate, 1% L-G1utamine, 1% PenicilUn and Streptomycin ,
(Gibco BRL, Canad ian Life Technolo gies, Burlin gton, Ont ario , Canada). The ce ll line
is unable to se c rete im munoglob ulin and lack s the hypoxan thine gua nine
pho sphoribo syhransferase enz yme. The Sp2/0 ' s were m ain tained very ca re fullywit h the
cells having greater than 90% viability and in lo g phase . The number of Sp2l0's for the
fusions was calculated as be ing I Sp2/0 cell : 10splee n cells to be fused .
I) The correct num b er of Sp2 /0' s were then pl aced in centri fuge tubes an d spun at 500
g for 10 minute s.
2) Both the spleen cell s and the Sp2 /0 's were washed 2 times in serum free medium,
DMEM con taining PIS.
3) Arter the second wash the Sp2l0's and the splee n cells were pooled (1:10 ratio) and
wa shed 2 more times with serum free DMEM PIS.
4) The supernatant wa s then poured o ff and the centrifuge tube d rained on sterile gauze.
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At this point the cells we re ready to be fused.
3.11.5 Fusion by Pipetting with Polyethylene Glycol
I) Aseptically. 1 ml of 50 % wl./vol. PEG was added via a pipette over 2 minutes.
directly to the pellet of cell s while constantly rotating the centr ifuge tube by hand.
2) 2 mls of alkaline medium were added over another 2 minutes as before.
)) 8 mls of alkaline medium were added over 2·) minutes. The total time for steps 1.2
& 3, was between 6 and 7 minutes and these times were deemed critical.
4) The cells were centrifu ged at 200 g for 6 minutes.
5) The cells were washed by adding 10 mls of serum free medium DMEM containing
PIS, without mixing up the cell pe llet. The preparation was centrifuged as before.
6) Celt s were then ready to be plated.
3. 11.6 Cell Platin g
A. Feeder mice spleens
Spleens from C3H mice were used for all fusions. The spleens were prepared as
described in Section 3.11.2. The spleenswere then placed in a sterile centrifuge tubeand
irradiated at 800 RAD. Irradiation was performed by the Radiology Dcpt., Health
Sciences Centre, General Hospital. The feeder mice splee ns were used at I x 10'
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cells/well.
H. Feeder Red Blood Cells
Feeder red blood cells were obtained aseptically from C3H mice. T he red blood
cells were placed in 10 mls of 10% Fetal Bovine Serum DMEM supplemented with 1%
sodium pyruvate, 1% L-Glut.aminc, I % Penicillin and Streptomycin, (Gibco BRL,
Canadian Life Technologies, Burlington, Ontario, Canada). The medium was first used
10 rinse a vacuratner, brand IOOx l6mm sterile tube for chemistry and selective
hnomarologydeter minants containing 143 USP units of sodium heparin (Becton Dickinson,
New Jersey, 07070). The medium containing the sodium heparin was then placed in a
15 ml centrifuge tube. Red blood cells were then counted as before and used al2 x 10"
cellsfwelJ.
C. Plating of Fused Cel ls
I) The fused B cells were then plated OI l I cell per well in 100 It! of HAT medium into
sterile 96 flat bottom micro-well plates with lids (Nunclon , Inter Med, Nunc, Denmark),
A density of 1.3 x 10\ spleen cells/well fusion procedure has been established in this
laboratory and this number has been found 10 give clonal growth of fused cells.
2) The plates were then incubated OIl 3'P C in a 10% COl incubator and the hybrid s
allowed 10 grow.
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3. 11.7 Hybridoma Feeding
I) Two days after plating, all plates were fed with loo p.l of :!X HAT selec tion m'cdium,
2) On Day 4, 100 p,1of mediu m were remo ved from all wells and 100 polof I X IIAT
selecton media were added.
3) The hybrids were then fed every 2-3 days with 100 p.1 of IX HAT, as in step 2.
4) The hyb rids were continuously monitored for grow th and, usu,1l1y on d;ly 10. the
hybrid supe rnatant was rich enough to be used for testing. Usually at this point the
hybrido mas had confluent growth in their respective wells.
3.1 1.8 Screening of Hybridom as
3. 11.8.A Primary Scree ning
Primary screening was perfo rmed by CELISA. All wells (fu$I',,1 H cells) plated
wer e screen ed. The supernatants of the various hybrids were tested again\! the
imm unizing cell. RAJ!. The only mod ification 10 the aforementioned CEL1SAbeing that
25 p.! of supernatant were incubated with 2.5 x 10" ce lls/plate of RAJ! ce lls in 25 p.1of
0 .5 % BSAlPBS. Hybrids tha t gave an optical density (0. 0 ) grea ter than 1.0 were kept
fo r further screening .
3. l t .8 .B Secondary Screening
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'The following homozygous cell lines were used (or scree ning the hybrid
supematanu : RAJI ; lBF; WT47; TOK; SAV C (9'* Interna tional Histocom patibility
Worbhop. held in Munich , West Gennany, 1984). Table 2 contai ns the haplotypes of
these cells as recorded in the literature.
Seconda ry tcsting was perfo rmed the day after the primary screen . A pool /miJtlUre
of cells (l OF. WT 47, TOK, SAVq was used in a negative selection proce ss with all the
supernatant being tested also agai nst the immunizing cell . The purpose was two fold; to
try and cut down the large number of hybrid s that passed the prim ary screen while at the
same time placing selectio n criteria ba sed on specifici ty upon the hybri ds . Quite simply,
the haplo types of the cell panel were not of interest end, thus, were selected aga inst.
Hybrids of interest included those that were producin g antibod ies agains t D RIO. DRJ and
selected DP epilo pes. Hyb rids that gave grea ter than 40~ posi tive against RAJI andless
than 10% positive against the cell mixture wen: selected for further testing. The
percentag e positive wascalc ulated by the Bio-Rad Microplate Manager /PC. DataAnal ysis
Software (Catalog 17Q.6617) (Rio- Rad. CA, USA).
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Table 2 : HLA alleles of cell pane l used in the secondary screen.
Cell Line HLA Alleles
Cia" I (' bss ll
A B C DR DO ,,"
PlJa l
RAJI' 23.30 8.13 - 3. 10 2 002
LBF 30 13 6 7 2 P1701
00201
Wf 47 32 44 5 13 6 PI"'I
00 1
TOK 24 52 - 15 6 IlO9OI
00201
SAVC 3 7 7 4 8 jJlOOI
00201
1
.. Raj i HLA type was obtained from Fisch, et aJ. (1989) and Socs, c/ s l. (1993). All
other cell line data came from the 11110International Histocompatibility Workshop,
Volume 1 and the 9'" Intemational Histocompatibility Workshop and Immunobiology of
HLA, Volume I , Histocompatibility Testing 1987 and Histocompatibility Testing :
Report on the Ninth International Histocompatibility Workshop and Conference, 1984.
- indicates that particular typing is unavailable
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3.11.8.C Tertiary Screening
The following homozygous cell lines were used for screening the hybrid
supernatants that survived the secondary screen : RA1I; SAVC; COX ; KASI16; YAR;
SLEOO5; 8304 (II '" International Histocompatibility Workshop number), (obtained
from the 1!Jl' International Histocompatibility Workshop, held in New York City,
USA, 1987). SAve was again used to c heck the secondary screen. Table 3 contains
the haplotypcs of these cells as recorded in the literature. Raj i' s HLA type was
obtained from Fisch, et el: (I989) and SOO£, et sl. (1993). All other cell line data
came from the I I'" International Histocompatibility Workshop, Volume 1 and the 9'"
International Histocompatibility Workshop , -- indicates that particular typing is
unavailable
All hybridomas that had reaction patterns seen in Table 4 were selected for
further screening. This selection process again eliminated all bybrid rrnas that were of
no interest, while at the same time allowing for a 'p robable' specificity determination
to be performed.
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Table 3 : HLA alleles of cells used in the ler1iary sen..-cn.
Cell Line HLA Alleles
Class1 Class II
A B C DR DO DP
13110 1
RAJ!" 23,30 8, 13 -- 3,10 2 ~ --
a02
SAve 3 7 7 4 8 iJ]OO]
a0201
COX 1 8 7 3 2 110..\01
001
KAS116 24 5 1
-
1 5 iJIJOl
00201
YAR 26 38
-
4 8 ~0401
001
SLE005 2 60 10 13 6 ~O30 1
001
8304
-- - -- --
-- /10401
002
Note : "-" dataunavailable
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Table 4 : Hybridoma testing selection pattern for tertiary screen.
CELL PANEL POSSIBLE
SPECIFICITY
SLE COX KAS116 RAJI 8304 SAVC
RX. + + - + + --- DPj31 69K
P
---
--- + + + --- DPPI 55·57
A
(AAE/EAE)
T
DP{J I 69K
T
E --- --- --- + - -- DRIO
R
N - -- --- + + -- DP
RX. : Reaction
Over 40% on a positive control report was considered (+) .
Le ss than 10% on a positive control report was considered (r-).
Possible specificity. refer to II " International Histocompatibility Workshop, Volume
I, p.617. 8304 : II'"International HistocompatibilityWorkshop number.
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3.1 1.8.0 Quaternary Screening
The following cell lines were used tor screening the hybrid supernatants :
RAJI; WTSI; DUCAF; BAI088; HOJOI; HAS301; P1-ll401S: KASOII; VAVY;
IBW9; TAB089; AMAI (obtained from the 9'" International Histocompatibility
Workshop, held in Munich. West Germany). All but two cell lines. BAl088 & RAJ!,
are homozygous. The BA1088 cell line originated from one individual whose B cel ls
were transformed with the Epstein Barr Virus in this laboratory. This panel of cells
allowed for a greater examination of specificity testing on the hybrids that survived the
tertiary screen.
Table 5 shows the haplotypes of the cell panel used. All cell line data came
from the 11'" International Histocompatibility Workshop. Volume I and the 9'"
International Histoco rnpanblltty Workshop, •• indicates that particular typing is
unavailable.
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Table5 : HLA allelesof cells used in thequaternary screen.
CELL HLA Alleles
LINE CLASSI CLASSn
A B C DR DQ DP
pI/cd
WfSI 23 6S 8 4 8 P02012
.01
DUCAF 30 18 S 17 2 PI0202
.01
TAB089 2 46 11 8 6 PQ202
002022
HASIS
-
-- -- 4 8 POSOI
a--
VAVY I 8 7 17 2 ,sOl01
a0201
RAJI 23.30 8,13
- 3.10 2 -
.02
BAlO88 29 7, 17
-
3, 10
-
-
Note"--" : data unavailable
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3.12 Cell Freezing
At least 2 x 10' total cells/vial were frozen. Nunc vw.!swert used (Nunc
Tube, Giboo Labora tories. Grand Island. New York, USA). Cells were first counted
as described before, and centrifuged at 1500 RPM for 10 minutes. I ml of freezing
solution, 10% Dimethyl Sulfoxide (J.T. Bake r lne., NJ, USA) and 90% heat inactivated
FBS (Giboo BRl, Canadian life Technologies. Burlington. Ontario. Canada), was
slowly added to resuspend the cell pellet. The freezing solution was kept at
approximately 4°C all the time. The cell suspension was then transferred 10 a chilled
Nunc tube and immediately placed at -700c. These vials were later stored in liquid
nitrogen.
3. I 3 Cell Thaw ing
Frozen cells vials were taken out of liqu id nitrogen and placed on icc. These
vial were then rapidly thawed by gently agitation in warm water (approx . 5<1'C).
containing common bleach, until there was only a crysta l of ice remaining in the vial.
The vial was them opened under aseptic conditio ns and the cell suspension pipcucd
into 10 mls of appropriate fresh medium. The cells were then washed twice at 1500
RPM for 10 min. and either placed in a 50 ml flask at a concentration of 3 x I O~
cells/ml or a 24 well plate with 20% FBS (Gibeo BRl , Canadian Life Technolog ies,
Burlington, Ontario, Canada) if the viability was low.
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3.12 Statistical Analysis
The following statistical testingmethods were employed in the analysis of the in
w\-O results: two way factorial ANQVA, mixed betwee n/within ANOVA, Dunnetts,
Tukeys and post hoc analysis.
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CHAPTER 4
RESULTS
4.1 The Effect of Administered Antibody on the Subsequent Serum Antibody
Response
Based on published literature it was expected that IgM antibody administered
before the injection o f antigenic nucleated cells would increase the subsequent serum
antibody response. Conversely , it was expected that IgG antibody should suppress the
subsequent response. Before these experiments could be attempted . it was necessary 10
tcst the chosen antibodies, 10 select some suitable cells to use as antigen and \0 gather
some baseline data o n antigen dO3€: response. In the next sections these preliminary
studies are described .
4.1. 1 Antibody Specificities and Purity Analysis
The antibodies have been described earlier with reference to class and
specificity in the - Materials and Methods~ section (Table I, page 40). Before using
them it was decided to check for any unanticipated cross reactions with mouse MHC
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or other molecules. The antibodies were also checked by gel electrophoresis for
purity.
4.1.1. 1 Test for Cross-Reactivity of NFLD.M65C3 andNFLD.M68CI 1C8
with Mouse:MHC and Human HLA-DR
Flow Cyromctry was employed to test whether the monoclonal a...tibodies
NFlD.M65C3, NFlD. M68C I IC8 and DPI39BD9 antibodies bind to mouse MHC
Class II antigens as well as to the transfectcd human HLA-DP antigens. Each cell line
was incubated with the appropriate antibody NFLD.M65CJ , NFlD.M68CI IC8 or
DPI 39BD9 then with specific conjugate, phycoerythrin labelled goat anti-mouse IgG or
IgM. Analysis was done on a FACStarf"'- Flow Cytometer.
Figure 5 sltow the results of experiments performed 10 investigate whether
binding of the NFLD.M 65C3 and NFLD.M68Clt C8 is directed against the transfected
Human HLA~DP antigens or if there is cross-reactivity with mouse MAC and Human
HLA-DR. Graph A shows cell lines tested against NFL.D. M68Cl l C8. Cell line LS56
is a mouse fibrob last transfected with Human HLA·D R, TIB209 is a mouse cell line
expressing IgM and mouse MHC only and L25.4 represents a mouse cell line
transfectcd with Human HlA·DP . As compared to the control there is no binding to
L'i56 or TIB209. There is significant binding to L25.4. Graph B shows cell lines
tested against NFLD. M65C3. Celt line A20 represents a mouse B cell expressing IgO
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and mouse MHC only. As compared to the control there is no significant binding 10
A20 or L556. There is. however. significant binding to l2SA. Graph C shows cell
lines tested against DP I39BD9 (non-specific mouse IgM). As compared to the control
neither cell line binds particularly well with DPI39 BD9. Thus, these results indicate
that NFLD.M65C3 and NFLD.M68C IIC8 are binding only 10 the human HLA·DP
MHC molecules thai are being expressed on the murine fibroblasts.
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UJ : OaI19JOC09'~L2·H'~L2·I~ i (lhl
C. DPJ39BD9
Figur e 5 : PACS analy:;is tu lcst lin' cross-reac tivity uf NFU).M65 C.1 (lgM),
N",U).M68C I IC8 {lgGl alld J)I'U9 U1YJ (lIUlh\pccilic IgM) ;wlihudics with lIIHllSC
MHC . L556 is a tmrse Iihrohlasllransfc<:tcd with human HI.I\ -DIt ; L25.4 is a
mou se cell line transfcctcd wifh human ULI\ ·I W ; TIIl201Jis a mouse B cell line
expressing IgM and mouse MHC; 1\20 a mouse B cell expressing IgU and mouse
M HC only. conno rs _. mouse L cell (expressing Class I MUq . This represents a
three dimensional plot of red florescence in log scale.
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4.1. 1.2 Test for Antibody Homogeneity
Th e next task was to grow the antibody secreting hybridomas, concentrate the
supcrnaram, purify and eheck for homogeneity. All antibodies were purified by
agarow gel affinity columns. In the case of the NFLD.M65C3 and DPI 39BD9, which
arc IgM antibodies, the concentrated overgrown supernatants were passed through anti-
mouse IgM (JI.--<:hain specific) - agarose columns for purification . The
~J F I.f).M6RC IIC8. an IgG antibody. was purified by the Affi-Gel Protein A MAPS II
Kit. Arter the correct amount of antibody was purified, gel electrophoresis (SDS-
PAGE) was per/armed to check for purity/homogencity. Figure 6 represents SDS-
PAGE performed on samples of NFLD.M65C3 and NFLD.M68CIIC8. The
molecular weight markers shown in Figure 6 consisted of markers from 14 400 MW to
97400 MW. All the antibodies were first checked in this manner before in WiV
experiments were performed. In this figure, one can see the heavy and light chains of
NFlD.M68C I IC8 (Lane 1) and NFLD.M65C3 (Lane 2). Upon comparison to the
molecular weight marker (Lane 3) the NFLD.M65C3 lane shows a clean sample with
distinct bands indicating the heavy chain between 97.4 Kd and 66 .2 Kd and the light
chain at approximately 29 Kd. The NFLD.M68CLLC8 lane displays a distinct light
chain band at approximately 27 Kd but the presence of a broad band or bands in the
heavy chain region .1\ approximately 51Kd. This may indicate the possibili ty that the
sample is a biclonal or oligoclonat as opposed 10 a monoclonal (gG antibody.
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Figure 6 : SDS-PAGE analysis of NFLD. M65C3 and NFLD. M68CIIC8 antibodies.
Lane I : NFLD.M68CIlC8. Lane2 : NFLD.M65C3 and Lane 3 : Molecular weight
markers. Bands were visualized via Coomassie brilliant blue.
79
4.1.2 Selection of Antigens
The next task was \0 select antigens 10 be used in the in Yiw experiments to
follow. It was decided that a human B cell line and a mouse fibroblast transfected
with human HLA·DP should be selected. The human B cell line, Raji, was chosen
based on work prior to this project (Samuels, 1992). This Honours Thesis had
considered such things as cell culture viability, expression of Class II antigens and
binding of varied ccll iines 10 the pan DP a ntibodies of IgM (NFLD.M65C3) and JgG
(NFLD.M 68C llC8) classes. The transfected mouse fibroblast provided human HLA·
DP molecules which would be recognized as foreign against a background of self cells,
thus, the enhancement/suppression response would be directed specifically to HLA-DP
determinants. However first, the most suitable transfectant had to be chosen.
A panel of HLA-DP transfected mouse fibroblasts (Table 6) were tested against
purified IgM (NFLD.M65C3) and JgG (NFLD.M6BC1ICB) by ELISA. Prior to these
and subsequent experiments a standardization of antibodies waas performed. The
minimum dilution that resulted in a significant absorbance at 490nm was selected. The
transfectants were used 24 hours after removal from the plastic culture dishes by
trypsin treatment. The ELISA was replicated. the pattern remaining consistent (Table
6). NFLD.M67 (IgG) has been extensively tested on a number of cell lines and mouse
transfected mouse fibroblasts in this laboratory and has been found to react with a
monomorphic determinant of HLA-DP, thus, this antibody was used as a positive
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control. The selection criterion was basic: to identify " cell line thai bound well with
the antibodies of interest, specific IgM (NFLD.M6.'iCJ) and specific IgG
(NFLD. M68CI IC8). Based on these tests il was shown that the 8JOS (L2SA)
rransfectant had the strongest binding with both IgM (NFLD.MbSCJ) & IgG
(NFLD.M68C I IC8). Thus, this cell line was chosen for the in "im experiments to
follow.
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Table 6 : ELISA results from a panel of silt HLA -DP transfectants tested against
NFt. 0 .M6.'iC3 and NFlD.M68CI IC8 antibodies.
CELL ANTIBODY TESTED
LINE (0 . 0. 490 nm)
10"" FBS NFLD .M67 NFLD. M65C3 NFlD.
DMEM M68CII C8
R305" 0.175 2.214 1.486 1.858
DV./JI3OIaO 1 0. 157 2.1 12 0.988 1.398
8.104' 0.178 1.940 0.611 0.901
DP/lOJOlaOl 0.192 2. 154 0.836 1.405
DP/10202aOl 0.184 1.871 0.702 0.937
DP/105OI a02 0.164 1.535 0.502 O.ID
.. II - Internalional Hislocompatibility Workshop numbers. Parental cells for all these
lines were mouse L cells. All cells are mouse fibroblasts that were transfected with
Human MHC, HLA· DP. Refer to Table I for specificity of NFLD .M6SC3 ,
NFLD.M67 and NFL D.M68CI IC8 antibodies. NFLD.M67 : Positive Control
10 % FBS DMEM : Negative Control (Blank)
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4. 1.3 Selection of Non-Specific IgM Antibody
It was not until the antigens had been selected that the non-specific IgM
ant ibody could be chosen.
Thus, the purpose of this experiment was to choose an IgM monoclonal
immunoglobulin that was non-reactive with the antigen of choice 8.105(L25.4). A
panel of IgM monoclonal antibodies were tested against two mouse fibmblasts
transfected with Human HLA·DP, the 8306 cell linc was known to react poorly with
HLA-DP specific IgM (NFLD. M65CJ) in past experiments so was included as a
"control". These results wcre replicated over a number of assays, each consistently
giving the same pattern of bind ing. From the results, Table 7, it can bc seen thatone
of these (DP139BD9) gave the weakest binding to 8305. As a result, il was chosen to
be used in the in yi K) experiment as the non-specific IgM antibody.
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Table 7 : ELISA results from a panel of IgM antibodies tested against 8305 and 8306
transfectant cell Jines.
ANTIBODY TE.STED CELL LINE (0 .0 49Onm)
8305* 8306·
10% FBS DMEM 0.352 0.411
NFLD.M67 2. 110 2.481
NFLD.M65C3 1.987 0.7 52
DP l68EHI 0.221 0.249
DPI69GE7 0.255 0.289
OPI43GG4C385 0.532 2.588
NFLD.M53 F69DH3H8 0.219 0.279
DP139DD9 0.210 0.319
GAM · IgM specific conjugate was used in the assay. Mouse fibroblast were
transfected with Human MHC, HLA-DP. * 1,110 International Histocompatibility
Workshop numbers. NFLD.M67 : Positive Control. HLA-DP specific IgM
(NFLD.M65CJ) was included again 10 recheck/check the binding with 8305, therefore,
also acting as a positive control. 10% FBS DMEM was used as the Negative Control
(Blank).
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4.1.4 Antigen Dose Response
Experiments were conducted to determine the 'optimal' dose of ant igen for the
in liw experiments to follow. The 'optimal' dose in these experiments would fulfil
two requirements; (I ) the dosage would be one thai did not result in a maximum
response such that the IgM enhancement could not be observed, and (2) conversely. a
dose in which the IgO suppression could be observed. These experiments were quite
straightforward . Groups of mice were injected with varying amounts of ce lls and
serum was collected at various time points. CELISA assays were then performed on
these samples so as to quantify the levels of antibody specific to the injected antigen.
A. RAJ!
The purpose of these experiments was to determine the 'optimal' dose of Raji
for the in liro studies to follow. The experiment consisted of gro ups of 4 C3H mice
injected intravenously with varying amounts of Raji cells; Group A : 5.0 x 10\ Group
B: 1.0 x 10'\Gro up C : 5.0 x l()'i, Group D 1.0 x lO T and Group E; 2.0 X 101• A
control group of mice was injected with sterile PBS. Blood and thcn serum samples
were collected from the animals on day 0, 8 and 14 and a CELISA was performed, as
seen in Figure 7. Time 0 represents the initial/existing levels of antibody in the
animals 2 hours prior to experimentation. It can be seen that with increasing doses of
injected cells, there was an increase in the subsequent antibody response each time; no
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plateau was reached in this dose range. A dose ors x 1()'lRaji cells/mouse was
determined to be used, as it allowed room for both an increase and a decrease rc be
detected resulting from antibody treatments. Standard error bars represent values
obtained from Ihe four mice comprising each group.
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Figure 7 : CEUSA results of groups of C3H mice injected with dirtcring doses of RlIji
cells. Note : each treatment group consisted of 4 mice; serum samples were
collected al day 0.8 and 14; graph represents antibody (1/800 dilution) specific for the
immunizing cell. Doses consisted of : Group A • 5 .0 x IcYcells/animal, Group R •
1.0 x I(f' cells/animal, GroupC - 5.0 x 10'" cells/animal, Group D - 1.0 X la'
cells/animal, Group E • 2.0 X 101 cells/anima l, a control group - sterile PBS, Standard
error bars represent values obtained from different mice.
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It L25.4
A similar experiment was also performed for the L25.4 cell line.
Consideration of the selection of the 'optimal' dose of L25.4 cells was identical as in
the case of the Raji cell line (4.1.4 Part A).
The experiment consisted of four groups of 4 C3H mice injected intravenously
with varying numbers of L2S.4 cells : Group A received 5.0 x Hr, Group B received
1.0 x 107, Group C received 2,S x 107, and an additional group of mice were injected
with sterile PBS. Blood/serum samples were collected from the animals on day 0, 6
and 12 (based on previous work (Samuels, 1992» and a CELISA perfonned as seen in
Figure 8. Time 0 represents the initial/existing levels of antibody in the animals 2
hours prior to experimentation. At Day 6 there is an inverse dose response (based on
the days assayed). animals receiving the smallest dosage 5.0 x 10"ce lls per animal
displayed the strongest response followed by the 1.0 x )07 cells/animal and 2.5 x 101
cells/animal treated groups , respectively. Higher doses of 2.5 ;II; 101 cells/mouse were
attempted, but the survival of the animals was jeopardized (i.e the an imals died). The
graphs show an unexpected~ in the serum antibody response with increasing
doses of these rransfectam cells. A dose of 5.0 x l()'i U5 A cells/mouse was selected
for the in \<1'1{J experiment
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Figure 8 : CELISA results of groups of C3H mice injected with d iffering doses of
L25.4 Cells. Note : Each group consisted of 4 mice: serum samples were collected
at day 0, 6 and 12, graph represents antibody specific for the immunizing cell (11200
dilution). Doses consisted of : Group A ·5.0 x l()'icells/animal, Group B • 1 .0 X
107 cells/animal, Gro up C - 2.5 X 107 cells/animal. a control group - ste rile PBS.
Standard error bars represent values obtained from different mice.
89
4.1.5 In t.fw Hapcriments
With all the elperimental conditions set, the neat step was 10 determine if IgM
enhancement and JgG suppression could be observed with the nucleated antigens that
had been selected. In all experi ments the antibody was administered intravenously 1-2
hours prior to intravenous injcction of antigen. All treatment groups consisted of 4
C3H mice. All mice were bled. sera obtained and a CELISA performed con the serum
sampjcs in order to quantify the primary antibody response directed against the
immunogen. NMS (normal mouse serum) represents sera obtained from all mice prior
\0 any manipulation.
4.1.5. 1 Pretreatment by HLA-DP specifc IgM (NFLD.M65C3) and HLA-DP
specific IgG (NFLD.M68CI IC8) with Raji as Antigen
In the first expcri rrcm tbe antigen used was the human B ce ll line, Raj i. The
experiment consisted of 4 grouP3of mice in which the antibody dose wasdetermined
""-0;00 on experiments contained in the literature (Henry and Jeme, 1968). Group A
received HI.A-DP specific IgM (NFLD.M65C3) (OA2mg/mouse) IN , Grou p B
received HLA-DP specific IgG (NFLD.M68C I IC8) (OA l mg/mouse) UV, Group C
rece ived stcril,~ PBS and another group. AB Alone. group received only HLA-DP
specific IgM (NF LD.M6."iC3) antibody. The NMS group represents the average (0 ,0)
of scm taken from all mice 24 hours prior to any manipulation. After 1.5 hours these
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mice were injected with oS x 10" Raji ce lls, IIV. At day 7, serum was collecte d from
each mouse and a CELISA performed. For each group Ig M and IgG levels were
individually detected by the use of a class specific conjugate , represented on the
graphic as M and G respectively . The AB Alone group represen ts the presence of
HLA-DP specific IgM (NFLD.M65C3) antibody at day 7 in mice not receiving
antigen, thus indicating the rare at which specific Ig M antibody disappears from Ille
circulation. It should be noted that the original design of this experiment included ,I
group of mice receiving only HLA-DP specific IgG (NFL D. M68C IIC8) nruiboey.
However, this particula r batch of antibody was found to be bacterially contaminated
after the experiment was conduc ted. thus, these data have been omitted.
Mice treated with HLA·Or specific IgM (NF LD.M MC3) did show an
enhanced primary response both in the IgM and IgO antibody levels at day 7, as
compared to the PBS contro l group (as illustrated in Figure 9). Statisti cally, this
di fference was significa nt (p< O.OOI. two way factorial ANQVA). The IgCi treated
grou p did show a lowered response in both IgM and IgO levels as co mpared to the
PBS control group. however, this difference was not statistica lly significa nt (p> IJ.05.
two way factorial ANQVA). The response displayed by the IgM pretreated animals is
in line with the results published to date in the literature (sec introduc tion) .
91
~ " " Q 'J I
§ . , ~ Ij ~ " ,
P II j []] r" nu"
~ ' H l l l'~ j
! 'I ' ;
A ~ ' I (: l j f
I II I ~ 1 ',I f u I
Figure 9 : CELISA results o f sera obtai ned at day 7 of C3H mice pretreat ed with
H LA-DP specific IgM (NFLD.M65C 3). HLA-DP specific IgG (NF LD.M68C IIC8)
a nd sterile PBS prior to admini stration of ~ x I ()& Raji cells/animal. AB ALONE
group represents animals only receiving HLA-DP specific IgM (NF LD.M65C3)
an tibody. NMS represents an averag e of sera obtained from every animal 24 hours
p rior to an y manipulation. T reatment s: Group A - NFL D.M65C3, Group B •
N FLD.M 68CI IC8. Group C • sterile PBS. M and G represent . respectively, IgM and
IgG specific conjuga te.
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4.1.5.2 Pretreatme nt by HLA-DP Speci fic IgM and HLA-O r Spec ific IgO
with HLA·OP Transfectant as Antigen
In this experiment the enhancement/suppression phenomena were tcslL'(Iill a
simila r experiment (Figure 9) with the DP transfectant (L2SA) ce lls as the antigen .
Group A recei ved HLA·D P specific IgM (NFLD. M65C3. O,34mglmo use) IIV. Group
B received HLA-OP specific IgG (NFLD ,M68CI IC8. O.30mgfmousc) ltv, and Group
C receiv ed sterile PBS. Prior standardization experimen ts resulted in a alteration of
antibody dosage in compariso n to the previous experiments, Th is d ifference may be
attributed to the differing antigens, After 2 hours these mice were injected with ~ x
10"tra nsfectan t cells, ltv , On days 6, 9, 12 and 16 sera were colle cted from each
mouse and a CELISA per formed. The AB Alone group represents the presence of
residual HLA·OP specific IgM antibody (NFLD. M6.'iC3) in circulatio n of mice
receiving antibody only. NMS represent s an average of seta obta ined from every
anim al 24 hours prior to any manipulati on . It should again be no ted that the original
desig n of this experiment included a group of mice receiving HLA -DP specifi c IgO
(NFLD,M68C1 IC8) antibody on ly. However . this particula r lot of antibody was
found to be bacteria lly contaminated after the experimen t was cond ucted, thus, this
data has been omitted.
The Ig M pretreated gro up showed an enhanced response from day 6 to 16
compared with the PBS treatment group (Figure 10). The IgO pre treated gro up's
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response to the immunogen was less than that of the PBS control at all times assayed.
The antibody alone group allowed for de tection of the antibody decay within the mice .
The NMS group allowed for a baseline prio r to experimentation and this value was
determ ined by averaging data from all the mice sera prior to experimentation. In
terms of 0. 0 units there was an increase o f about fourfold due to the pretrea tment
with specific IgM antibody and a decrease of approximately 50%due to the
pretreatment with specific IgG antibody on day 6. The maximum en hancement by
IgM was observed on Day 6. The maximum suppression by IgG was observed on Day
9.
Treatment and days, as well as the interaction between the two, were all
significant (p<O.OOI, mixed between/within ANOVA). Since the ANOVA analysis
indicated a significant interaction, a detailed post hoc analysis was pe rformed. It was
found that the HLA·DP specific IgM (NFL D.M65C3) and HLA·DP specific IgG
(NFLD. M68C II (8) treated groups were significantly different from the PBS control
on all three days tested (p<O.O I . Tukeys).
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Figure to : CELISA results of O H mice pre treated w ith HLA·D P specific IgM
(NFLD .M65CJ ), H LA·DP specific IgO (NFL D. M68C I1C8) an d PBS prio r 10
ad ministrat ion of 5 x 10"cel1~ani mal DP tran sfceted fib roblast s (ili.4) . Serum
samples were taken at Day 0 , 6. 9, 12 and 16 . Treatments: Group A - specific Ig M,
Gro up B - specific IgO, Gro up C M St erile PBS . NMS represent normal mouse se rum
and the AB Alone g roup rep resents the antibody decay (animals receiving only HLA·
DP specific IgM ant ibody, NFLD.M 65C3). Mi xed Ig M and Ig O specific conjuga te
was used.
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4 . 1.5.3 Pretreatment by H LA-DP speci fic IBM and Non-specific IgM wit h
H LA·DP transfect ed fibrob la!t as An tigen
As presented in the introducti on, the lit erature suggests that one of the
characteristicsof Ig M enhancement is that the response is antigen (putide) speci fic but
nOl epito pc specific . In ord er 10 veri fy that th is. an ex periment was per formed in
which an imals were pretrea ted with non-speci f icIgM. DPI39 BD9, and HLA-DP
specific IgM antibody (NFlD.M65C3) before immun ization. This information was
important for the planning of experiments de sc ribed in the second section of this thesis.
Fro m Henry ' s and Je ree's (1968 ) expe riment the results clearly indicated that
as the animals recei ved inc reasing a mounts of ISM an tibody. the primary response
be came stro nger a nd stronger. It wa s decide d to repea t the p revious experiment
a dding an e xtra group. that being non -specific IgM (J-igure 10). and, in an altem ptto
im prove on ue tre mendous enhance ment see n in the previous study,the animals were
ad ministered appro ximately twice as much antibody. Group A received Hu'-D P
specific Ig M (NFL D.M65C3. O.68mglmouse) W . G roup B received a non-specifi c
IgM (OPI 39BD9. O.62mglrn Ollsc) UV . andGroup C received sterile PBS. Mte r 1.5
ho urs these micewe re injec ted with 5 x 10" L25.4 ce lls, IIV. On days 6 . 10 and IS,
serum samples were collec ted from each mouse and a CELISA performed. AD Alone
[tl"01:P rep resents the presence of antibody in mice only receiving HLA-DP specific
Ig M (NFL D.M6SC J) antibod y.
96
The NF L D.M6SC3 pretreated group did ex perience an increase in the response
to U 5A as com pared to lhe PBS control g roup (Figure I I) . Unexpectedly. Ihe
DP139 8D9 pretreated g roup also experie nced an increase in the response 10 L25 ,.$. as
compa red 10th e PBScor, trol. H owever. Ihis respo nse was nol as st rong as the HIA -
DP specific Ig M (NFLD . M65C3 ) adminis tered gro up. The NMS group is the~Iinc
obtaine d froma ll anima ls prior to experi mentation. The A ntibOlJy Alone group
represe nts the d ecay of H LA·DP specific IgM (NF LD.M6."iC 3) antibody with in the
mice.
Statisticall y, both treatme nt and day s had a signific ant effect on outcome
(p< O.OOI. mix ed between/with in ANOV A) . How ever, there was no significan t
interac tion (p> 0.05. mixed between/with in ANOVA). POSI hocan alyses were
therefo re perfonned separa tely fo r treatme nt and d ays. Fo r ueamem. both the
specifi c IgM a n d non·s peci flC IgM differed from th e PBS con trol (p > O.OI. D unnels).
Ford a ys, day 6 differed from d ay 10(p < O.OS. Tuleeys); da y 6 di ffered from day
IS. a nd day to differed from da y IS (p < O.OI. Tulceys).
This stud y diffe red from the previous expe riment in two sig nificant ways : a)
twice a s much specific IgM anlibody was used. b ) a non-specifICIg M antibod y ueatcd
group was included . S urprising ly. doublin g the speci fic Ig M antibody concen tration
did not increase the enha nceme nt seen in the previou s expe riment. Rather. upo n
comparison the relative enhance ment dim in ished. Th is lower respo nse may be due to
the existe nceof an optimum of administered IgM antibody and a concentration above
this docs not aid in enhancing the primary response. Inot her words, thedose of the
IgM a ntibodies mayhave been too high. Whencomparing theothe r groups of the tw o
experiments both the PBS control groups gave similar optical density readings (appro x .
0.60.0), however, the AB Atone group, representing the antibody decay, produced
an optical density approximately 4.7 times higher than the previous experiment (0,7 'IS.
0,150.0 ), Since twice as much antibody was used . this gr oupwas expected to give
higher an abso r bance reading perhaps twice as high , than seen in the prior experi ment
but not 4-1 limes as high . Standard error bars represe nt values obtained from different
mice.
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Figure 11 : CELISA results of C3H mice pretreated with HLA·DP specific IgM, non-
specific 19M and PBS prior 10 administration of 5 x 111'L25.4 cells/animal. Serum
samples were take n at Day 0, 6, 10 and 15. Treatments: Group A - HLA-DP specific
19M(NFLD.M65C3 ), Group B - 't en-specific IgM (DP I39BD9), Group C - sterile PBS.
NMS represent norm al mouse serum prior to manipulation and the AB Alone group
represents the antibodydecay (animals receiving only DP specific IgM- NFLD.M65C3),
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4.2 Effect of Ad ministered Antibody on the Popula tion of Hybrido mas Harvested 3
Days After Antigen.
The follo wing C:lperiments were conducted base on the hypothesis that the IgM
antibody could innuenceJenhance the production of hy bridoma s with specificities thaIour
laboratory was inte rested in developing. These "hybri do maso f interest" are specific for
HLA-DR and HLA·DP molecules. Th is laboratory is part icular ly imerested in obtaining
hybridomas against; DPPI 69(K), DPtll 55-57(AAEl EA E) and DRIO. Thus, the idea
was to use as an imm unogen , a cell line containing the afo rementionedsequences. Before
these experiments could be attempted, it was necessary to deter mine the full HLA type
of the chosen immunogen. Raji cells, and to determine a dosage for the subsequent
experiments to fo llo w. These experiments, in conjunct ion with the results obtained from
the previous in lIiKJstudies, provided the informatio n necessary 10 design the fusion
experiments. In the nel t sect ion the preliminary stud ies are described.
4.2. 1 HLA Type De termination of Raj i
HLA typi ng of Raji cells was carried out by (I) Complement Dependent
Cytctcxichy Typing Platesand (2) HLA -DP typing via a monoclonalantibody panel. The
partial HLA type o f Raji ce ll s has been published. The se experiments were conducted in
order to confirm the report s and to fill in the 'gap s' in these reports. It was also
necessary 10 know the HLA type o f the immunogen 50 as to choose cell lines with
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appropriate HLA types for the screening proce ss that would determine the vario us
specificitiesof the resultant hybridomas.
4.2.1.1 HLA Type Determination via CDC Typing Pbtes
From previous work by Fisch. et a1. (1989 ) andSoos , tt et. (11)9]) it Wil!. 5t:lIcd
that the HLA typeof Raji cells was A 23 .30; 8 8. 13; C not typed; DR3, 10 S2i DQ 2;
DP unknown.
Complement de pendent cytotoxic (CDC) HLA typing plates obtained from the
Canadian Red Cross Soci ety were used to verify the claims presented in the literature a nd
to identify the C locus .
The reading/scoring of theseplate s/welts was partic u larlydifficu lt. The typing was
attemptedthree times each with varying results. As a result the A and Blocu s could not
be typed with certai nty due to irregularity. The:problem s wen: a comb ination of
inexperience. dead celts and complement toxicity. Mo re expe rienced people in the
laboratory alsotypcd Raji cells but met willithe same lac k of success. However. the DR
10 and DRw52 types d id rema in consistent. Also, with re spect to the C loc us, the Cw3
haplotypewas consisten t in all theexperiments.
4.2.1 .2 HLA ·DP Determination via Monoclonal Antibod ies
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DP typin g was not avai lable with the Canadia n Red Cross Society's C DC typing
plates. For investiga ting the HLA-DP type. mon oclonal antibodies produced in th is
laboratory were used. Thesean tibodiesrecognize knownepi tcpes o f expressed DPQ' and
(j chain s. Tab le 8 shows the DP,81amino acid seq uences assoc iated with thei r respective
HLA-DP alleles and the monoc lonal anti bodies used , with their re spective specificities.
For e xample. the M120 antibod y recognizes an epitopeconferredby the"GPM" motif a t
amino acid 85 -87 and expre ssed by the DP ,IJI 150 1. ISOI. 2801 ,3401alleles . Thus, thi s
antibody will bind to cells expr essinga ny of these "DP ty pes".
ACE LlSA, tes ting these monoclonal antibodies aga inst the Raji cell line was then
perfo rmed as seen ill Tab le 9. Additiona l monoclonal antibodies were tested. along wi th
some 'Jf the monoclonals previo uslyteste d in the C ELISA. using FACS analys is (as see n
in Figure 12). For bo th assays the positive and negative con trols were identica l;
NFLD.M67 (an antibody against monomo rphic ALA·OP de terminants) wa s used as th e
positive control. while 10% FBS DMEM served a s the nega tive co ntrol. An absorban ce
readin g (490nm) greate r or equa l to 1.0 was consideredas po sitive. Ascan be seen from
the readings. the diffe rence betw een po sitive ab sorbance readings (eg. NFLD.M1l 8 :
2.24) and negative readin gs (eg . NfLD.M73 : 0 .106) was us ually large (Tab le 9). Tab le
10 summarizes the re sults o f all the monoclon al s tested against Rajl. NFLD.M66.
NFLD.106. NFL D.MI17 and NFLD,Ml 18antibodi eswere testedby CELISA and FAC S
with both assays produ cing the same result. Additional antibod ies tested by FACS
included NFLD .Mlll. NFLD.M I14, NFLO.Ml 18. GGPM (Table 10). The associa ted
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epltopes for these an tibodies as well as possible DP types are listed in Table 8. For
example. the M58 epitope is DE at position 55-56 {31 c hain. In reference to publ ished
sequences, this ephcpe is pre sent in DP/11 020 1, 0301.. .••.3501. Therefore . thisantibody
w ill bind to cells expressing any of these DP types. Similarly for the rest of the
ant ibodies in Table 8.
The monoclonal antibod ies with mapped epitopes could then be matched wilh
known HLA-DP types (fa bl e 8). By comparing the results of the monoclonal a ntibody
panel from both the CELISA and FACS assays, one could eliminate a number of HLA-
DP and epitope possibilities. From Table9 and Figure 12, Raji was positive (bound 10 )
monoclonals NFLD.M66 (DEAV, 84-87), NFLD.M 70 (DPa0 2) and NFLD. MIIR
(DPa-02) but negative agains t the re maining panel. Based on comparisons within Table
8. Rajican be partially typed , with respect 10 HLA-DP. as having cnc (homozygous) or
an y two in combination (heterozygous)of the following Hl A type s a: 2; (3: 0101. 1101,
1301,2101 , 2701,3001 .
Wi th respect to the monoclo nal antibodies that reacted positively with Raji cells
the related epitopes can also be exa mined (Table 11). Table I I presents the possible
HLA-DPj31 types with assoc iated epitopes after the positive and negative reacting
monoclonal antibodies 10 Raji cells have been cross checked {within Table B). By this
metbod Raji cells could be partially epilope typed as having. a t positions 84-B7 OHi\V.
With respect tel the other hypervarieblc regions, of interest , the possibilities were
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narrowed down to :
35-36 : VA
55-51 : AAE or EAE
69 : K, R or E.
84-81 : DEAV (definite).
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Table 8 : DPP1 amino acid sequence variation s and their associated haplotypes .
AMINO ACID SEQUENCE HLA·DPnl
DE
55-56
MS8
M60
M73
MIOI
M1I2
DEE
55-57
MI06
DEAV
84-87
MONO CLONAL ANTIBODIES
Mill M66 MYE901
M il S GGPM
MII 9
POSSIBLE HLA -DP T YPE
GrM
85-87
MI20
LV/FV
35-36
Mill
M77
0201 0201 0301 0101 0201 \501 0201
0301 0402 0601 0301 0202 1801 0202
0402 OBOI 090\ 0501 0401 2801 0401
060I 1001 1401 060I 0402 3401 0402
0801 1601 l701 0801 3201 0501
0901 1801 200 1 0901 3301 0801
1001 2801 2901 1001 1601
1401 3501 1101 1901
1601 1301 2201
1701 140l 2301
1801 1601 2401
2001 1701 2801
2501 1801 3101
2801 190I 3201
2901 2001 3301
3201 2101 3401
3501 2701
2901
3001
3101
3501
M'" antibod ies refer to NFLD .M## monoclonal antibodie s.
Cf OJantibodies : NFLD .M I14 & NFLD .M11 6
Cf 02 antibod ies used : NFLD .M I18 & NFLD .M70
From Il lb International Histocompatibility Workshop and Conference. Volume I, p.615-618.
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line.
Table9 : CELISAresults of a panel of monoclonal antibodiesagainst the RAJIcell
ANTIBODY ABSORBANCE (49011,">
TESTED RAJI CEllltNE
NFLD.M67 1.480
10%FBSDMEM 0.110
NFlD.M.58 0.09.5
NFLD.M60 0.091
NJ'LO.M66 0.400
NFLD.M70 0.437
NfLD.M13 0.147
NFLD.Mn 0.111
NFLD.Ml06 0.106
NFLD.MI12 0.""
NFLD.MIIS O.IOS
NFLD.M1J6 0.106
NFW.MI17 0.121
NFLD.MI 18 2.240
NFLD.MI19 0.129
NFLD.MI20 0.110
MYE90\ 0.0917
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Figure 12 : Flow Cytomctry results of various meooclonal antibodies tested lIga i n~t the
Raji ce ll line. NFLD. M67, an antibody against monomorphic IILI\ -UPd cterminants, was
used as the positive control, while 10% FBS DMEM served as the negative control.
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Table 10 : Summary of Row Cytometryand CELISA results in the investigationofRaji's
HLA·DP type by monoclonalantibodies.
ANTIBODY RESULTS
TESTED (f'OSm VElNEGATIVE)
CEUSA F1~
Cylomt"ll)'
NFW.MS8 N'O NT
NFW.M60 NEG NT
NFLD.M66 N'O NEG
NFlD.M70 PO, NT
NFLD.M73 NEG NT
NFLD.M77 NEG NT
NFLD.M IOfi N'O NEG
NFLD.M I12 NEG NT
NFLD.M IIS NEG NT
NFLD.Mllb N'O NT
NFLD.M I 17 N'O NEG
NFLD.M I 18 PO, PO,
NFLD.M I19 NEG NT
NFLD.M I20 NEG NT
MYE901 N' O NT
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Table 10 : cont'd
ANTIBODY RESULTS
TESn D (POSITIVE/NEGATIVE)
CEUSA FkJW
Cy ltllt1ct l)'
NFLD.Mll l NT NEG
NFLD.MII4 NT NEG
GGPM NT NEG
NOTES :
NEG: Negative
POS : Positive
NT: Not Tested
The results have beencompiled from Table9 and Figure12.
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Table II : Summary of possible HLA-DPI31 epnopesof Raj i cell line as a resultof
monoclonal antibodytesting by Aow Cytometry andCELISA.
POSSIBLE POSSIBLEHU,-DPj3IASSOCIATED EPITOPES
H LA- (VARIATIONOF AMINOACIDS)
DPPI 35-36 55-57 fn 84-87
TYPE
0101 YA AAE K DEAV
1101 YA AAE R DEAV
1301 YA AAE E DEAV
2101 LV EAE E DEAV
2701 YA AAE K DEAV
3001 FV EAE E DEAV
From I)·Inlemational Histocompatibility WorkshopandConference,Volume I, p.615-
618.
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4.2.2 Spleen Dose Response of Immuniza tions with Raji Cells
In the following experiments the purpose was 10determine the dose of Raji for the
fusion experiments to follow. Since the aim of this section was to enhance the production
of hybridomas specific to Class II HLA determinants, it was decided to maximize all
aspects of the experiment. In other words, choosing the best dosage of antigen to elicit
a maximum primary response.
In order to accomplish this, groups of 2. eleven week old female C3H mice were
injected with varying amountofRaji cells intravenously; 1,5 x 101,3.0 x 107, 5.0 X 10',
6.0 X101 and 7.0 x 107 cells/animal. A control group receiving only sterile PBS was also
included. Injections of 7.5 x 10' cells were performed twice but resulted in the animals
dying almost immediately after injection in both cases. When administering the 7.5 x 101
cell dose, heparin injected with the cells did improve the success of the injection (also
seen in the administration with the higher dose of DP transfcctants). However, since thc
effects of heparin are not completely understood (Ihrcke et al. 1993), it was decided nol
to unnecessarily complicate the experiment with an unknown factor and no experiments
were performed with a 7.5 x 107 group. The spleens were removed at day 3, post
injection, and the total cell count performed.
As can be secn from Figure 13, the splecn size increased as the dose of cells
increased up to a peak at around a dose of 6 .0 x 107 cells. Based on these data , it was
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decided that an immunization dose of 6.0 x 107 cell s P" mouse would be used for the
fusion experiments to follow. Thls would allow for a strong response as seen by the total
spleen count, while at the same time administering a dose at a level that would allow the
animals to remain in good health until the comple tion of the experiment.
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Figure 13 : Spleen size in relation 10 Raji dose. I I week old female C3H mice were
used. Each treatment group consisted of 2 mice. Counts represent total spleen cell
number. The 0 dose represents an administration of sterile PBS.
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4.2 .3 Fusion Experiments
These experiments investigated the effect of differing amounts of a preexisting
HLA·DP specific IgM antibody (NFlD.M65C3) on the production of hybridomas specific
to Class II HLA, especially HLA·DR and HLA-DP. Throughout the results these
antibody producing hybridomas are termed "hybrids/hybridomas of interest". These
"hybridomas of interest" are against HLA-DR and HLA-OP molecules. This laboratory
is particularly interested in ob taining hybridomas directed against; DPfJI 69{K), DP,I31 55-
57(AAE/EAE) and DRIO, as previously mentioned.
With the preli minary work completed, the fusion experiments were performed.
BaS«!on previous work in this laboratory, spleens were harvested at day 3 after antigen
administration. Prior 10 the fusion experiments , C3H mice had been used for the studies
reported in this thesis. Fl hybrid mice were chosen for the fusion experiments. The Fl
hybrid mice were obtained from a cross between Balb/c and C3H mice. Previous
experiments in this laboratory had indicated that the Fl hybrid mice produced hybridomas
with a wider variety of specificities as compared to the C3H mouse strain. Thus, the PI
hybrid was used 10 maximize the resultant yield ofhybridomas to HLA-DP and DLA-DR
molecules. The P I hybrid mice had not been used in the spleen size experiments (Figure
13) due to a lack of availability.
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The design of the experiment called for three groups of 4 FI mice. Within each
group, three of the four mice were pretreated with purified antibody while the fourth
mouse acted as the control receiving sterile PBS. Mice were first injected intravenously
with antibody and, within 1·2 hours . injected intravenously with antigen. 6.0 x 101 Raji
cells. The three treatment groups received : 2.63 mg/mouse, 1.31 mg/mouse and 0,47
mg/mouse of purified HLA·DP specific IgM antibody (NFLD.M65C3). The animals
were then sacrificed on day three and the spleens aseptically removed. The spleen cells
were then fused with the myeloma cell line Sp2/0 . The resulting hybrids were plated out
in a suitable dilution such that each well would contain approximately one hybrid cell.
The hybrids were allowed to grow and were then screened against a number of cells with
known HLA types so as to determine their specificity.
4.2.3. t Spleen Size at Day 3
When the spleens were removed from the animals, counts were performed to
determine the total spleen size before and after T cell depletion. These figures are shown
in Table 12. 1.3 x 10' spleen cells/well were plated, This fusion procedure has been
established in this laboratory with the afore mentioned cell per well number found to give
optimum clonal growth of fused cells. It has been observed in previous fusions, in this
laboratory, that the B cell T cell ratio is roughly 50:50. Thus, after the magnetic-bead
T cell depletion method, there should be approximately 50% recovery, for example, in
Table 12 the percent recovery after T cell depletion should be approximately 50%
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(assuming that the 8 cell T cell ratio is 1:1). The control group displayed 38.4~
recovery. All the IgM treated animals had a greater recoveryas compared to the control
group, 89.1" for the 0.47mg IgM. 45.2" for the1.31mg JgM and 40" for the2.63mg
IgM, thus suggestingthat the spleensdid not consist of the 50:50 Bcell T cell ratio as had
beenexpected.
The dataalso suggest that themore IgM antibodyadministered, the more T cells
there arc in the spleen and conversely, the lower the IgM dose, the more 8 cells present
in the spleen. It makes intuitive sense that the more 8 cells in the spleen, the more
hybridomas and the better chance of obtaining the desired specificities.
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Table 12 : Percentage recovery of spleen cells after T cell depletion prior to fusion with
the Sp2lO partner cell.
TREATMHIT TOTAL AFTER PERCENT
G ROUP SPLEEN T CELL RECOVERY
COUNT DEPLETlON OF NON·T
(, 10') (11 10") CElLS
0.4 7 mg IgM 4.6 4.1 89.1%
1.3 1 mg Ig M S.6 2.S 45.2%
2.63 mg IgM 65 2.6 40.0%
CONTROl. 1.9 0.13 J~ .4%
Spleens from IgM treated mice (3 mice per grou p) were pooled and T ce ll
depleted. Groups of th ree mice had been pretreated with 0.47, 1.31 or 2.63 mg of IBM
antibody and 1-2 hours later immunized with 6 11 10 J Raji cells/ani mal. Splcens from
each IgM treated group (3 mice) were pooled and T cell deple ted . Controf mice were
pretreated with PBS, then immun ized wit h 6 11 10 J Raji cells/animal. Thecontro l splccn~
were not pooled and represe nt an average number. The total splcen cells after T cell
depiction were fused. After fusio n the cells were plated at 1.3 x lit cells/well .
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4.2.3.2 Primary Screen Hybrid cells against Raji
At approximately day 10. the supernatants of the hybrids were considered to be
rich enough to undergo the first screening procedures. This time was selected based on
past fusion experiments conducted in this laboratory. The screen was carried out by
CELISA with each of the hybrid supernatants being tested against the immunizing cell,
Raji. This allowed for selection of all hybridomas that were specific for the immunizing
cetlline.
An hybrids having an absorbance reading (49Onm) of greater or equal to 1.0 were
considered positive and kept for future screening, The average number of viable hybrids
was estimated by counting plates at random (columns 3. 7 and I I) and noting the number
of viable hybrids. Plates counted for each fusion were ,as follows :
A. 0.47 mg IgM group 13126 plates were counted.
Control 4 14 plates were counted.
B. J.3J mg IgM group 10119plates were counted.
Control 7/7 plates were counted.
C. 2.63 mg IgM group J1120plates were counted.
Control 515plates were counted.
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The percentages of immunogen reactive hybrids were calculated by determining
the number of positive hybrids as seen in the primary screen and dividing by the result
of multiplying the average number of hybrids per plate and the number of plates for each
fusion group.
Table 13 shows the number of immunogen reactive hybrids for the different
fusions as a result of the primary screen. The cont rol animals were grouped together for
analysi s. Treatment groups of 1.31 mg and 2.63 mg of I ~M antibody gave a lower
number of immunogen reactive hybrids (9.3 and 17.7. respectively) as compared to the
contro l grou p (29.3). However , the low dose uf 0,47 mg antibody produced a higher
numbe r of immu nogen reactive hybrids (101) as compared 10 the control group . Thus.
at this point the data suggest that pretreatment with a low dose of IgM antibody (0.47 mg)
may enhance the number of antigen specific hybrido mas (as seen in the primary screen).
wherea s the higher IgM doses are associated with an unexpected reduction of specific
hybridomas.
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Table 13 : Percent positive immunoge n reactive hybrids as seen in the primary screen.
AVG. # AVO. # OF # OF
TREATMENT VIABLE POSITIVE POSITIV E
GROUPS HYBRIDS HYBRIDS HYBRIDS
(PERSPLEEN) (PER SPLEEN) (%)
0.47 mg IgM 123.9
'0' 81.5%
1.31 mg lgM 92.5 9.3 10. 1%
2.63 mg IgM 96.7 17.7 18.3 %
CONTROL 63.6 29.3 46.1%
Th e average number of viable hybrids per spleen was estimated/calculated by counting
plates at random. Columns 3. 7 and I I of each plate were scored for the number of wells
with viable hybrids. The number of immunogen positive hybrids was determined by
CE LlSA, these hybrids reacting positively against Raji. Percentage immunogen reactive
hybrids were calculated by :
% Positive hybrids ::;: Avg. (J of Positive Hybrids per Spleen
~~ ~ - ~ -- ~ -~-----_._~----------- X 100
Avg. # Hybrids/plate x # of Plates for each Fusion
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4.2.3.3 Secondary Screen
The secondary screen involved a negative selection process. All hybrids were
tested within 24 hours of the primary screen. The cell lines used were : LBF. WT47.
TOK and SAVC. These cells were pooled and tested by CELISA (i.e all cells were
placed in the same wells). Table 2 gives the HLA types of these cells. The hybrids wen:
also tested separately, against Raji (by CEI.ISA) to confirm that the hybrids were
secreting anti-Raj! antibodies (immunogen specific). Hybrids were chosen for further
screening if they were negative against the cell panel and positive against the immunizing
cell. This selection allowed for a rapid method of eliminating hybrids with specificities
that our lab was not interested in, and in doing so the large number of hybrids was
dramatically reduced to a manageable number. To accomplish this, a cell panel
containing such HLA types was used (Table 2). This selection was based on a pe rcentage
positive report. Cells giving greater o r equal 1040 % positive against Raji and less than
or equal to 10% positive against the cell mixture were chosen. Thus. if the hy bridomas
supernatants did not react with the chosen panel and did react with Raji, those hy bridcmes
went on for further screening.
As can be seen in Table 14, in the treatment group of 1.31 mg IgM a ntibody, a
greater percentage of hybrids (71.4%) of interest resulted from the IgM treated animals
as compared to their controls (38.6%) . In the case of the 0.47 and 2.63 mg IgM group.
the control group produced more hybrids of interest, (25.0% and 37.7% respec tively, as
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compared to the ccnrol 38.65). Percent posi tive was ea lcutaed by di viding th r number
of hyb rids of interne by the total n umber of hybrid s screened.
Thus, upon comparisonlel imination of thehybridomas with the HLA type s of the
cell pane l, the specificity of the hybrido mas continuing on to the te rtiary screen, with
respect to lhe im munizin g cell can be pro posed as possibly being : Clas s I : A 23, B 8 ,
e? (no l S,6,7) ; Class II : DR 3 or 10, D Q (eliminated). DP 002. 13 '1(not 170 1. 1601.
0901, 1(0 1).
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Table 14: Pe rcentage o f positive hybrids as seen in the seconda ry screen.
TREATMENT AVO. # AVO. ... OF PERCENT'
GROUPS HYBRIDS OF HYBRIDS POSmVE
INTEREST SCREENED
PO ST SCRE EN IN SCREEN n
<PE R SPLEEN} (P ERSPLEEN)
0.47 mgl gM 25.3 10 1 25. 0%
1.31 mg IBM 6.7 9.3 71,4 %
2.63 mgIgM 6.7 17.7 37.7 %
CONT ROL 1l.3 29.3 38 .6%
Th e hybrid s of inte rest were determined bya negative selection p rocess against a poo l
o f cell line s , LOF, WT 41, T O K and SA VC w h ile reaeti ng~itivcly with Rajiin a
CELISA. Pe rcent posit ive w as calculated by d ividing the number of hybri ds of
interest by the total number o f hybrids screened.
123
4.2.3.4 T e rtiary Screen
Th e tertiary screen involved another panel of cell s in a further att empt to
narrowdown the selectedhybrids toward s HL A·DR or HLA-DP specifici ties by
CEUSA. Thecelllires used in this screen in cluded : SAVe , cox, KASJl6, Y AR,
SLEOOS. 8 304 and Raji. The 8304 cell line i s a mouse L cell lraIIsfected with human
H LA·DP. Table 3 givts the HLA type s of th e se cells .
Tab le 4 give s the reac tion pa tte rnsof the hyb rid s that were selec ted for furt her
screening with thei r (possib le) respec ti ve specifi cities. From th is selec tio n, hyb ri ds
ha ving po ss ible specificitie s for HLA- DP, particularly DP,Bl: 69 · K, 55·j 7 · AA E
a nd/or EAE and H LA-DR IO were se lected.
Table 14 sh ows the hybrids o f interest resulting from the tertiary screen. 1lle
con trol grou p gave a higher percentage of hy brids of interest (Sj.8~) as compared to
the 1.31 and 2.63 mg IgM treated group (j.O% and 15.0" re spectively) . However,
the 0.<l1 mg group r ave a higher pe rce ntage of hybrids ofinte rest (61.7 %) as
co mpared 10 the control (55 .8"). W hen 100king more closely at theco n trol gro up,
the result ing 19 hy brids of interest of the34 hybrids screened originated from th e
Two distinct reactio n panems emerged from thi s scree n: either the bybrids of
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intere st were posit ive on Raji an d negative on the remainin g cells (indicating a possib le
HLA-D RIOa n tibody) o r litehybrids were positive on Raj ; and8304 (indica ti ng a
possib le HLA- DP antibody), (8304 is a m ouse fibrob last cell line transfected with
huma n HLA·O P, expressing 0102 and,80401, Table 4). Th e majority of the hybrids
selected fitted the HLA·D RIO pattern. O f the 74 hybrids selected 68 (91.9%) fitted
the D RIOand 6 (8.l %) theHL A·DP pa ttern, Fu rthermore, of the hybrids se lected
that indicated a HLA-D RIOspecificity, 5 1 were p roduced frommice pretreated with
ISM antibody (the majority of hybrids resulting from the 0.47 mg IgM dosa ge' 48).
with the remain ing 17 hybrids originating from th e contro l group. Whenlook ing at
the possible HLA-DP antibodies , the IgM treated animals produce d twice as many
antibodies as compared to the control group, 4 H LA-DP resulting from the 0 .47 rng
treatment of antibody and 2 from tileco nt rolgroup.
Thus, a t the end of the tertiary sc reen,d ue to the consistency of the reaction
patterns of the hybrids, it was possible to eliminate certain specificities to w hich the
hybri ds were not direc ted. All tlteselec ted hybrids had fa iledto react with the
followingcell lines: LBF, WT47, TOK, SAVe. SU:005, co x or KASI 16 in
CELISA scree nings. Therefore , with respect 10 the immunizing ce lls HLA type, the
hybri ds selected so far maybe directed against H LA Class I : A 23, B(eli m inatcd), C
7 (no t 5, 6, 7 ) ; with respect to HLA Class 11 : DR 10, D P 1lI02, IJ7 (not 0301, 0401,
0901 , 1001, 1301, 160 1,1701) .
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Table 15 : Percentage positive hybri ds as seen after the terti ary scree n.
TREATMENT # HYBRIDS TOTAL PERCENT
GROUPS OF INfEREST HYBR IDS POSITIVE
SC R EENED
0.47 mg IgM 51 76 67.7%
1.31mg IgM 1 20 5.0%
2.6) mg lgM 3 20 15.0%
CONTROL 19 3' 55.8%
The hybri ds of interest we redetermined from Table 4 which gives the reaction penems
of the h ybrids that were selected with their (possible) respect ive spec ificities. Percent
positive wascalculated b y dividing the number of hybrids of interest by the total
number orhybri ds screened.
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4.2.3.5 Quaternary Screen
The founh screeninvolvedCELlSA testingaga inst a further 6 cellline s :
DUCAF. BAI088. HASIS. VAVY. TAB089. Wl'SI and Raji. DAJ()88 and Raji
were lheonly non-homol)'gouscells. BAI088 (8 cell) was prod ucedin this !.aboralOf)'
by Epstein Barr vi ru s transformation: thecell lineorig inatedfrom a penon typed as
having DR IOHLA type. The panel of cells allowed for a grea ter examination of
specificity testing o n tilehybrids. Table 5 gives the HLA types of these cells.
Thus. with respect to the immunizing cells HLA type. the hybrids selected arter
this screen may be directed against HL A Class 1: A (ruledout). B (ruled out). C 1
(nor S. 6. 7. 8. II ); with respecr to HLA Class II : DR 10. DQ (ruled out). DP 002.
13 '1(not 0 101. 02012 . 0202. 0301. 0401. 050 1.090 1. 1001. 10202. 1301. 1601.
1701). At this leve l. hybridornasreacting with the BAI 088 and Riji ce ll line were
definedas a possib le anri·HLA·DRIO.and thoseTUCling only with Raj i indicating a
possible anti-HLA-DP (Table 5). Pastreaction pattern s withal1 the various cells were
alsocompared in order 10ensure these designations.
Table 15 g ives the number of hybrids of interes t resulting from the quaternary
screen. Within the 0.47 mg group. the IgM treatedan imals gave a higher percentage
(45.1%) of hybrids of interest asco mpared to the control group (36.8%). The 1.31
mg IgM treatment groupdid notyield any hybrids o f interest. The2.63 mg treatment
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group produced an equal number of hybrids of interes t as compared 10 the control
group, 33.3 % vs. 36 .8%. Again, o ne mouse within the contro l group produced the 7
hybrids o f interest with no contribution from the two remaining control animals. The
0.47 mg treatment group prod uced a relatively equal nu mber of hybrids of interest
within the test gro up .
From comparisons with all the cells tested against me selected hybrids, the IgM
treated mice produced 21 an ti·DRIO and 2 ant i-HLA-DP antibodies. From the
controls there were 7 anti·D RIOantibodies created. W hen loo king at the original
number of hybrids created, as determined by the primary screen , a comparison of the
percentage of hybri ds finally selected at the end of the fourth screen can bemade.
From the 0.47 mg treatment group the pretreated IgM animals produced 23 hybrids
secreting antibody against C lass II HLA·DR and HLA-O P, 23/101 or 22 .8%. The
con trol group produced only anti·HLA·DR antibodies, 7/88 a yie ld of 8 .0 %. The 1.31
mg group did not yi eld any hybrids of interest. The 2. 63 mg pretreated IgM animals
produced I Class II HLA-D P antibody 1/53 or 1.9%. Animals given Ihe lower dosage
of IgM antibody, 0 .47 mg, did seem to have a better overall yield of an tibody
formation to Class 11 MHC determinants as compared to the t .3 t mg and 2.63 mg
gro ups with the specificity predominately directed agai nst HLA-D RIO molecules.
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Table 16 : Percentage positive hybrids as seen in the quatern ary screen.
TREATMENT # HYBRIDS TOTAL PERCENT
GROUPS OF INTEREST HYBRIDS POSITIVE
SCREENED
0.47 mg lgM 23 'I 45.1%
1.31 mg IgM -- I
-
2.63 mg IgM I 3 33.3%
CONTROL 7 19 36.8%
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CHA PTER 5
DISCUSSION
Alth.ough the experiments reported here have confirmedin a general waythe
earlier published resul ts, namely thatpret reatmentwith antigen specificIgM antibody
facilitates an enhanced primary response andconversely the pretreatment with antigen
sped fieIgO antibody mediates a suppressed response,the re were several unexpected
findings. These includ e a reverse dose response whentran sfectant cells were used as
an immunogen: an appa rent red uction of the IgM enhance ment when higher doses of
IgM were used: a curious effec t on the half life of IgM in yjvo, where high doses
seemed 10 lead toa lengthening of the half life and finally an interesting effect of
specific IgM on the nu mber of T cells in thesubsequently immunised spleen. These
points will be discussed in tum which will be followed by an attem pt to understand the
complexdata collected during the fusion experiments. In a last sectiona plan for
future research ispresented.
S. I In Ww Experiments With Mouse Transfectant and Human B CellLines
In the in 11111 experiments, certain protocols were adapted fromstudies
reviewed in the Introduction. Modifications made 10the experimentalprotocol were
time of antigen injection (1-2 hourspost antibody injection), route of injection (UV)
lJ<)
and amount of antibody ad mini stered . All these variables were previous ly optimit.cd in
their respective experi ments . with the findings adapted to the experiments designed in
this thesis project.
5 .1 . 1 Reve rse Dose Response With TT;JJ\$fectan ts
Interestingly . the two immunogens, USA and Raji, disp layed di ffering dose
responses (Figure 8). The hu man B cell line, Raji gave the expected dose response:
with increasing dosage increa sing the response, whereas the L celltransfcctant line,
L25.4, gave an inve rted response . A dose o f 5 It 10" L25A ce lls/animal gave the
highest a ntibody re sponse and , incre asing the dosage to 1 It 10J and then 2.5 It 10'
ce lls/animal, actually resulted in a progressively lower product ion of antibody. The
most like ly Clplanat ion for this is that the hig her cell doses may be: ac tually ind ucing a
degree of tolerance. Such a -high dose loleJ<lJ'lCe- effect is well recognized especially
for weak anligens (Matzinger , 1994). Since L25A is a transfected mou se:fibrob last
e xprus ing Human HL\-DP molecules (origi nating fo rm a C3 H mouse) , when these:
ce lls are injected into a C3 H mouse , the animal will see only the expressed Hu man
HLA·DP antigens as foreign. In con trast, the Rajicell line is a human B cell
lymphoma. When presented in a mouse, the animal will recogn ize the entire
repertoire of expre ssed hum an antigens as fo reign and subseq ue ntly a vigorous
response will be mo unted. Thus, the Raji cells arc a much stronge r antigen than the
L25.4 ce lls. The finding that it may be difficult to ind uce tolerance with strong
131
immunogens (Matzinger, 1994) also provides supporting evidence for the discrepancy
between immunogens. This 8 cell tolerisation may also be a result of the route of
injection (intr.tvenously) and/or the high dosage of antigen administered (Nossa!, 1992;
reviewed in Abbas et al. 199 1). 1be experiments in this study showed that the Raji
cell line did not demonstrate any reduction of the response even with an administration
of 2 ill: 101 cel ls/animal (intravenously). Further experiments are worth conducting. To
initiate an investigation of this phenomenon, cell dose experiments could be performed
starting at quite low doses of I x 10' L25.4 cells with gradual incre ments to I x 1(1
cells/animal. As always, it would essential that enough mice be used in the groups to
allow the data I" be statistically significant. It would also be interesting to see if cells
such as L556 (mouse fibroblast transfected with human HLA·DR) also demonstrate a
tolerisation effect at high immunizations.
5.1.2 In \.fKJExperiments with Raji as Antigen
The in rim experiments were first conducted with Raj i cells as the immunogen.
This experiment showed that animals pretreated with specific IgM antibody displayed a
significantly enhanced response as compared to thecontrols (Figure 9). Sera were
collected on day 1 and tested separately with IBM and IgG specific conj ugates to
determine respective changes in primary antibody levels. Animals treated with specific
IBM antibody displayed a statistically significant enhancement of the serum antibody
directed against Raji with respect to both IgM and IgG levels as compared to the PBS
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control. This confirmsexperiments in the literature in whichredblood cells were
usedas antigen and showing IgM enhancement (Heyman.I9'XJb). Coeverseiy,animals
treatedwith specificIgGanlibodydisplayed a diminishedanti·Raji IgM and IgG
responseas compa-ed tc the PBScontrol. However. in this case. whenstatistical
analysis was employed thedifferences werenot signifICant. This maybe due to the
IgG antibodybeing admmiatered at a sub-optimum dose. To test Ihis. a similar
experiment should beeoedectedin which a range of specific JgGantibodyis
administered in order to identify this optimumdosage for the ISO suppression. This
would also be worthperforming for the IgM mediated enhancement. Consideration
should also be given to whether the IgG suppression effect is influenced or not by the
antibodypurification protocol.
05.1.3 In \110 Experimentswith iliA Cells as Antigen
5.1.3A Initial Elperirncnl
The firstexperiment. oondUCIed with L25.4 as antigen.nOl: only di!playeda
tremendous enhancement facilitated by the pretreatment with specifIC IgM anlibody but
also demonstrateda suppressedresponse mediatedby speeiflc IgG antibodyupon
comparison with the controls (Figure 10). BoIhtne observed enhancement and
suppression werestatistically significant. This again confirms experiments in the
literature in which red bloodcells used as antigenshowed specificIBM mediated
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enhancement and specific IgG mediated suppression (Heyman, 1990b). Thus, this
phenomenon, earlier described by Henry and Jerne (1968) has been established to exist
when the antigen used is nucleated cells, namely a human B cell lymphoma; Raji and a
mouse fibroblast transfected with human HLA-DP; L25.4.
5. 1.3.8 Diminished Response with Doubling of Antibody
An unsettling observation was made in the second set of experiment s with the
L25.4 cell line (Figure II ). In this experiment treatment groups consisted o{ one
receiving specific IgM antibody, another receiving non-specific antibody and a control
group identical to the previous experiments. The previously demonstrated
enhancement mediated by specific IgM antibody diminished drastically in this
experiment . The ' non-specific IgM' antibody actually appeared to enhance the
subsequent {ormation of antibody , rather then have no affect as had been anticipated.
Upon further comparison to the previous experiment with 1.25.4 (Figure 10), an
additional factor was altered. that being the administered antibody dosage.
5.1.3 .81 Antibody Dosage
In comparison to the previous experiment (Figure 10), in an attempt to improve
the enhanced response of the IgM antibody, larger doses of both the specific and the
non-specific IgM antibodies were administered. This alteration was based on the
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observation made from the experiments of Henry and Ierne (1968) who clearly showed
that there exists a direct linear relationship between the degree of enhancement and the
administered dose of the IgM antibody as demonstrated by red cell antigens and anti-
red cell antibodies with plaque forming assays. However, some researchers have
shown, in contradiction to these experiments, that there is an upper limit to the effect
of IgM antibody pretreatment, beyond which the response ceases to display the
characteristic enhancement (Dennett, 1971; Powel et al. 1982) .
One possible explanation for the results in Figure I I is that the 'uppe r limit'
may have been passed in this experiment. It would be interesting to pinpoint the
optimal dosage of administered antibody. A range of doses for pretreatment with IgM,
IgG and the non-specific IgM antibody could be examined, for example. from 0.1 mg
to 1.0 mg of antibody per mouse in 0.1 mg increments. The experimental design
would consist of treatment groups of at least 4 mice per group. The control group
would not receive any antibody treatment. The animals would be bled p-tor to any
manipulation so as to detect existing IgO and IgM antibody levels. The animals would
then be injected with the appropriate antibody and 1-2 hours later with antigen. The
animals could then be bled every third day for twelve days and the serum assayed.
Another concern cornu from the rate of decay/elimination of the administered
antibody. The high level of detected antibody in circulation within this experiment
(Figure 11), as compared to the previous one (Figure 10 ). suggests that there is a
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limit to the amount of antibody getting to the spleen . This limit may have an
important role in the IgM and JgG mediated modulatio ns. It would be interesti ng to
investigate if tissues othe r than the spleen also take up the administe red IgM an tibody.
If this is the case , the method of capture/uptake would also be interesting to know. If
othe r tissues are not found to be involved, how is this excess antibody and/or antibody-
antig en complexe s destroyed . A preliminary investigation into these queries could be
initiated by desi gning an experiment in which different gro ups of mice receive a broad
range of IgM antibody. Serum samples would then be taken at consistent time
intervals. Duplicate and /or multip le grou ps, for the varying doses, would allow for
obtaining tissue samples at the different time s. Both serum and tissue samples voutd
then be assayed for the presence of the administered antibody .
5.1.3 .82 Non-specific IgM
A review of the IgM enhancement phenomenon states that the antibody used for
pretreatment must be antigen specific but not epitope specific (Heyman 1990b) . To
test this , a non-specific IgM antibod y was used. This antibody was chosen based on
previous Flow Cytometry analysis (Figure 5) and CELISA results (Table 7) both
demons trating extremely low binding with L25.4. According to the cited literature , it
was expected that this non-specific IgM antibody would have no enhancing capacity in
this experime nt. This was not the case since the non-spec ific antibody treated group
actually media ted a small degree of enhancement as compared to the controls. Thus ,
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the specificity of the 'non-specific' IgM antibody can be questioned. II may be
possible that there was some small degree of specificity or unanticipated crossreacrivi ry
with this antibody, and this may provide an explanation of the observed slight
enhancement. Selecting a non-specific IgM antibody for further experiments would
involve testing a panel of IgM 'non-specifics' against a number of different cell lines
with known specificities. This would allow for an extensive demonstration of
specificity.
5. 1.3.83 Actual Amount of Antibody and Antigen Received
Another factor 10 be considered in this second set of experiments with L25.4
(Figure t 1), is the actual amount of administered antibody and antigen the animals
received upon injection. Since intravenous admin istration of antibody and antigen was
particularly di fficult due to the size of the tail ve ins, records were kept as to the
'success' of injections for all experiments. These records indicated that the
administration of both antibody and antigen was not ideal for all the animals in this
experiment. This problem must beconside red when interp reting the results. If this
experiment is to be repeated, as with any of the in liw experiments, it would be
convenient to have extra animals, antibody and antigen on hand when performing the
injections. This would allow the investigator to select mice with a smaller margin of
error in the actual amo unt of antibody and antigen received by the animals. while at
the same time maintaining a treatment group number that is statistically significant.
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Thus, the above described experiments demonstrated that the
enhancement/suppression phenomenon described by Claudia Henry and Niels l em e
(1968) is also observable with nucleated antigens. With this observation made, the
application of this phenomenon to the creation of hybridomas was then investigated.
5.2 Fusion Experiments
For the fusion experiments FI hybrid mice were utilized, while the in wm
experiments employed C3H mice as did the preliminary spleen dose response
experiment (Figure 13). The spleen dose response experiment utilized C3H only due
to the lack of availability of the FI hybrid mice. In an effort to maximize specificit y,
variability and viability of the hybridomas, this laboratory has used FI hybrid mice.
The FI hybrid mice contain a heterozygous array of MHC molecules, originating from
Balb/c and C3H parents. It was hoped that this heterozygosity would also lead to
more variability in the anticipated increased cell response. The fusion partner cell for
the FI hybrid B cells was the Sp210 cell line. This cell line originated from a Balb/c
mouse. The second rationale for using FI hybrid mice, was to minimize any B cell
(experimental animal) anti-fusion partner cell response that might develop. Previous
experiments conducted in this laboratory indicated that these hybrid mice produced a
wider variety of specificities as compared to the homozygous mouse strains used (for
example Balb/c, C3H).
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5.2.1 Choice of Antibody
The criterio n for the specific IgM antibody used for pretreatment is that it had
to have strong binding to the antigen of choice . The antibody need not be epitope
specific but had to be antigen specific. The IgM antibody used was speciflc fer a
monomorphic determinant of HLA-DP. This antibody had already been shown 10 have
strong binding with Raji (Figure 5) and had demonstrated a strong enhancement when
antibody was used to pretreat animals prior 10 injection of the Raji cell line (Figures 9
and 10). The proposed in \lim mechanism of enhancement is that the effective
trappingllocalization of antigen within the spleen is facilitated by specific IgM antibody
(see Introduction). On hindsight, if the specific IgM antibody is acting in such a
manner, with the antibody binding to HLA·DP epitopes, it may have been better to
have used an antibody against monomorphic HLA-DQ or other determinants which
efficiently bound to Raji, but which may have left the HLA-DP and HLA-OR specific
epitopes more exposed to be recognized or bound by B cells in the spleen. This may
have a resulted in a more productive yield of HLA-OP and DR antibodies. At a
purely speculative level, this explanation may also account for the predominance of
HLA-DR specific hybridomas observed at the fourth screen as a result of the use of
the HLA·OP specific IgM antibody.
5 .2.2 Spleen Analysis
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5, 2.2A Spleen Size and Dose of Antibody
There was an effect on spleen size of increasing doses of specific IgM
antibody. As the dose of IgM was increased from 0.47 mg to I.J I mg to 2.63 mg per
mouse the number of cells of the spleen rose concomitantly from 4.6 x 10" to 5.6 x 10"
106.5 x 10". Several points need comment here.
First, the spleen size went above the previous plateau demonstrated by
increasing doses of Raji cells. This may be a result of a particular mouse strain effect,
f l versus C3H mice and will need further exploration by a direct comparison of the
FI and C3H mice. One should first investigate if a plateau effect exists, as described
with C3H mice, with increasing doses of Raji cells. Following this, one would
investigate varying doses of specific IgM antibody in groups of Fl and C3H mice.
From these results, with proper controls and sufficiently large numbers of animals, a
comparison of the Iwo strains would bepossible. It would be established if specific
IgM really does lead to an increase in spleen size in relation 10 antigen dose and/o r if
the "maximum size" can be exceeded.
5.2 .28 Spleen T Cell Composition
Second. although the spleen cell number was increased, it was apparently
mainly due to an increase in T cells. The number of B cells, after T cell depletion,
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decreased with increas ing IgM doses. This curious observa tion has evidently nol been
made before . Further. investigation may identify the type ofT cell population found
in the spleens. Onecan speculate mat the T cell population is co mposed of mainly
CDS· cells, with the real possibility that some type of suppn:s.sive mechanism is
involved. If by T cell population analysis there indeed is a.predominance of CDS' T
cells, this cou ld be investigated by conducting :1J1expcrimenr in which the spleens arc
depleted o f their CDS ' populat ion and the original experiment repeated. This may
provide a way of further enhancing the response. In this situatio n, it follows that the II
cell population would be increase d and thus, the final rcsult might bean increased
number of hybridomas with varied specificities.
S.2.3 Specifi city Analysis
S.2.3 .1 The Screening Rationale
The ultimate goal of the screening strategies was to identify and select certa in
the specifici ties of the hybridomas crea ted after the fusion. Due to the enormously
large number of hybridomas created it was necessary 10 develop a strategy which
facilitated the rapid elimination ofh ybridomas that were nocof interest. The
hybridomas o f interest for this study were defined before the onset of these
experiments as being HLA·DR and HLA-DP specific, particularly those directed
against DPtl l 69(K), DPtll S5·S7(AAFJEAE) and DRIO.
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The first screen was conducted by CELISA in which the immunizing cell, Raji,
was jested against the supernatants from all the viable hybridomas created. This
immediately selected for all the hybridomas that were antigen specific. As can be seen
from Table 13, there wasa marked reduction in number of hybrids initially screened
(1130)and the number of positive hybrids selected (4n). The selected hybrids then
were tested with a series of screening panels of homozygous cell lines. This made
possible the rapid elimination of hybridomas and elucidation of specificities of those
remaining.
The second screen was a negative selection process. The selected hybridomas
were tested against a panel of homozygous cell lines (Table 14) all of which had HLA
specificities that were of no interest. Thus, hybridomas whose supernatants bound
with Raji cells and did not bind with the panel, were chosen to be carried forward to
the next screening. A concern bere is that this screen eliminated many types of anti-
IUji hybridornas, including those against Class I polymorphisms and monomorphic
Class II determinants of all kinds. Theoretically, the IgM facilitatedenhancement is
'part icle dependent' (!ICeIntroduction) and thus, all anti-Raji specificities should be
increased. Although manyspecificities were eliminated through the selection process,
the selected specificities of interest should also be increased and this should be
demonstrated by direct comparison between treatment groups, a reference/control
group, all of which had undergone the same selection criteria.
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For the tertiary screen a reaction pattern was developed that would indicate the
possible specificities of the screened hybridomas (Table 4). In this way, the
hybridomas specificities were further narrowed and the number of hybridomas
reduced. At this level, all of the selected hybridomas displayed a reaction pattern
suggesting either a possible anti~DR or anti-DP specificity. This may lead one 10
suspect the possibili ty of the pretreatment of specific IgM to specifically direct a
response. At this stage this is purely speculative and would need further study 10
verify . The fourth screen used yet another panel of homozygo us cell tine; further
elucidating the hybridomas specificity. The panel contained a heterozygo us cell line
(BAI088) which expressed the HLA-DRJO antigen (Table 5). Hybridomas reacting
with the BAI088 and Raji cell line were defined as a possible anti-HLA-DRIO, and
those reacting only with Raji indica ting a possible anti-HLA-DP (Table 5). Past
reaction patterns with all the various cells were reanalyzed in order to ensure these
designations.
The cell line panel chosen was composed of lines that were not problematic to
grow and that were available in this laboratory. A larger panel of cell lines would
have provided bette r spec ificity definition if readily available.
5.2.3.2 Specificity of Resultant Hybrido mas
In the fusion experiments , three doses of IgM antibod y (O.47mglmouse,
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l.B mg/mc use and 2.63mg/mouse) were administered to three groups of mice, all
containing control animals. This was done in order to test whether an tibody
pretreatment dose affected the number or variety of hybridomas created [particularly
those with specificities deemed of interest). When 0.34 mg/mouse of specific IgM
antibody was ad ministered the enhancement was clearly significant, however, when the
dosage was doubled to 0.66 mg/mouse (Figure I I) it was not. Thus. dosage of IgM
antibody may have an important role to play in the enhancement phenomenon. One
must be careful in adapting this finding to fusion experiments, since maximum
localization of antigen in the spleen by the pretreatment IgM antibody may be
important in the development of monoclonals to particular epltopes of interest
(especially those that have been problematic), than the quest of solely enhancing the
response. In othe r words the antigen must be trapped, faci litating maximum
presentation 10 the B cells.
The experiments suggest but do not prove that treatment with low dose of
specific IgM increases the yield of specific hybridomas.. Animals pretreated with
0.47mg IgM antibody gave a 22.8% yield of HLA-DR and DP monoclonals, whereas
jhe control group produced an 8% yield of only HLA-DR monoclonals. Compared to
the other IgM dosages, the 0.47 mg dose contributed 96% of the total HLA·DP/DR
selected monoclonals. Allhough there was much individual variation in control
animals, nevertheless, on a percen tage basis, the IgM treated animals clearly produced
more anti HLA-DP and HLA·DR hybrids. For future experiments it will be important
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to use far more animals in orde r to accurately determine the effect of the specific IgM
antibody. In addition, animals in the treatment group should he fused separately.
rather than pooled before fusion, in order to compare individual variation in these
groups with those of control animals.
5.3 Future Directions
These pilot studies of the enhancement/su ppression phenomenon using nucleated
cells indicate thai this technique warrants further investigation. As mentioned in the
Introduction, the exact mechanism(s) involved in IgM facilitated enhancement is not
fully understood. Experiments to elucidate the mechanisms would involve careful
plan ning with innovativeapproaches. The results, however , would beof great value
no t only on a pure imm unological level but also for practical applications.
The role of the FeR receptors should be investigated . Since one of the
postulated mechanism of IgO suppression involves crosslinking by immune complexes
of FC'YRJIB and antigen receptors on B cells, it may be possible to use genetically
altered mice that have a FcR'Ychain deletions (Ravetch,I994). An experiment might
involve groups of mice , including an FcR'Y"knockout" gro up and two corresponding
gro ups of strain -matched, normal mice one receiving the exact treatment as the
"knockout" group and one without antibody pretreatment. In this way further insight
to the regulation of B cell activation and the role of FeR's might be obtained. This
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type of design also could also be used 10 examine the role of FcR)' in IgM
pretreatment.
Interestingly, in one of the earlier experiments cited, (Wiersma et aJ. 1989), it
was demonstrated thai with a panel of9 IgG monoclonal antibodies, only 5 were able
10 suppress the response 10 SRBC's. This may also hold true for the DP monoclonal
antibodies chosen, including the IgM antibody. Thus, future experiments shoold
investigate a panel of specific IgG and IgM DP monoclonal antibodies to determine if
such a phenomenon exists with DP and in order to select the best antibody in both
The usc of othe r specific IgM antibodies against, for example. monomorphic
determinants to HLA·DQ , might be more useful for developing monoclonals to HLA-
DP and/or HLA-DR epitopes. Trapping the antigen by the HLA-DQ molecules would
leave the HLA·DP and HLA·DR molecules more exposed, optimizing the presentation
and subsequently enhancing the formation of antibodies 10 epitopes that until now have
proven vel)' problematic. It would be necessary 10 conduct an experiment with one
gmu.' of mice receiving an anli-HLA·DQ IgM specific antibody. another an anti-Hl.A.
DP IgM antibody. and a control group receiving sterile PBS. All the mice would then
be injected with the same antigen, and after fusion the resultant hybridomas screened
for specificity. It then would be able to determine if an IgM antibody specific to
HLA·DQ dete rminants is better o r worse than a monomorphic HLA·DP IgM antibody
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in the creation o f hybridomas to HLA -DP and HLA·DR cpitopcs.
Although this project tested the effec t of preexisting antibody levels on the
primary response only, it might be possible to apply these findings 10 the secondary
response. An e xperiment might invo lve a setup in which a sub-optimal dose of antigen
is given and, a fter the primary response dissipates (i.c. serum antibody levels fall close
to normal). the animals cou ld then be administered specific IgM antibody and
cha llenged with the same antigen. In this way the secondary response might be
"boosted or optimized" . T his technology might further increase lhe chance of creating
hybridomas speci fic for a varied nu mber of cpitopes 10 poorly immunogenic molecules
(for example. HLA-DP), This method might also increase the chances of obtaining
hybridomas specific to epitopes thai until now have proven to be elusive.
The hybri doma production experiments performed in this thesis can be viewed
as a pilot study of one method to improve conventional fusion methodo logy whieh has
relied on repeated immunisations prio r to fusion for the production of monoclonal
antibodies .
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